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Resumo 
 
O carcinoma de células renais é a neoplasia renal mais comum e compreende três principais 
subtipos histológicos, sendo o carcinoma de células renais de células claras (CCRcc) o mais 
prevalente e agressivo. O CCRcc é frequentemente caraterizado pela perda, mutação ou 
silenciamento epigenético do gene supressor tumoral Von-Hippel Lindau (VHL). A inativação do 
VHL e consequente acumulação do fator induzido pela hipoxia (HIF) leva à ativação de vias de 
sinalização associadas a um contexto de hipoxia. Nomeadamente, a produção do fator de 
transformação α (TGFα) conduz à ativação do fator de crescimento epidérmico (EGFR). 
Adicionalmente, estudos demonstraram a sobreexpressão do EGFR e o aumento da sua 
estabilidade na membrana de células de CCRcc. Os doentes de CCRcc desenvolvem resistência 
às terapias aplicadas na clínica, pelo que existe a necessidade de desenvolver novas estratégias 
terapêuticas que ultrapassem estas limitações. A desregulação do EGFR pode ser a base para o 
desenvolvimento de novas terapias dirigidas. Recentemente, os exossomas têm surgido como 
novas ferramentas terapêuticas dada a possibilidade de serem modificados e escaperem ao 
sistema imune. Estas vesículas extracelulares de 30 a 150 nm podem mediar a comunicação 
intercelular através do transporte de moléculas bioativas (proteínas, DNA e microRNAs 
(miRNAs)). O GE11 é um péptido que se liga especificamente ao EGFR e pode ser expresso na 
membrana dos exossomas, permitindo especificidade de ligação. Em última instância, estas 
vesículas extracelulares podem ser carregadas com RNA de interferência (RNAi), pequenas 
moléculas de RNA que controlam a expressão genética a nível pós-transcricional. Estudos 
recentes demonstraram o envolvimento de miRNAs na regulação do eixo VHL/HIF, e 
consequentemente das vias de sinalização relacionadas com o EGFR. Os miRNAs são pequenos 
RNAs não codificantes responsáveis pela regulação de inúmeros genes a nível pós-transcricional. 
Estudos bioinformáticos revelam que a p53 pode ser um dos alvos do miRNA-1233. A p53 regula 
os níveis de HIF através da degradação mediada pelo MDM2. Desta forma, o miRNA-1233 é um 
candidato promissor a alvo terapêutico visto que poderá regular os níveis da p53 e consequentes 
respostas de HIF relacionadas com a hipoxia. Portanto, o objetivo deste estudo é avaliar o uso 
de exossomas positivos para o GE11 (GE11+) como um veículo de entrega para o potencial uso 
de RNAi em CCRcc. No presente estudo, foi usada uma linha celular caraterizada como 
metastática de CCRcc, FG-2, duas linhas celulares epiteliais do túbulo proximal de rim, HKC-8 e 
HK-2 e uma linha celular embrionária de rim, HEK293T. De acordo com os resultados obtidos, a 
linha celular FG-2 apresentava níveis de expressão do mRNA do EGFR (P<0.001) e níveis 
proteicos do recetor superiores comparativamente à linha celular HKC-8. A via de sinalização 
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MAPK/ERK encontrava-se sobreativa uma vez que a linha celular FG-2 apresentava níveis 
superiores da forma ERK2 fosforilada comparativamente à linha celular HKC-8. Estes resultados 
realçam a importância do EGFR no desenvolvimento de CCRcc e o potencial uso de um sistema 
de entrega ao EGFR baseado em exossomas. A manipulação da linha celular HEK293T permitiu 
a obtenção de exossomas com o péptido GE11 na membrana. Estes exossomas foram marcados 
fluorescentemente e incubados com as linhas celulares HK-2 ou FG-2 a 4°C ou 37°C durante 4 
horas. A 4°C observou-se uma quase completa inexistência de internalização dos exossomas em 
ambas as linhas celulares, sugerindo que as células devem estar biologicamente ativas para que 
ocorra a internalização de exossomas. Relativamente à incubação a 37°C, uma percentagem 
mais elevada de células FG-2 internalizou os exossomas GE11+ comparativamente aos 
exossomas derivados de HEK293T transfetadas com pDisplay, a condição controlo (97% e 92% 
respetivamente, P<0.001). Adicionalmente, observou-se que as células FG-2 que internalizaram 
os exossomas GE11+ apresentavam uma mediana de intensidade de fluorescência 1.4 vezes 
superior comparativamente ao controlo (P=0.001), sugerindo que cada célula terá internalizado 
um maior número de exossomas através de um mecanismo dependente de EGFR. 
Relativamente à linha celular HK-2, não foram observadas diferenças de internalização de 
exossomas GE11+ e o controlo, visto que os níveis proteicos do EGFR eram inferiores 
comparativamente à linha celular FG-2. Em suma, foi possível observar uma diferença 
estatisticamente significativa dos níveis de internalização dos exossomas GE11+ entre as linhas 
celulares normal e tumoral (22% e 97%, respetivamente, P=0.001). Contudo, estas diferenças de 
internalização não se deveram exclusivamente aos diferentes níveis de expressão do EGFR entre 
as linhas renais, uma vez que se observou uma diferença entre os níveis de internalização na 
condição controlo (19% e 92%, respetivamente, P<0.001). Em conclusão, o uso de exossomas 
GE11+ pode constituir um novo sistema de entrega de RNAi em CCRcc. Estudos iniciais 
demonstraram que o miRNA-1233 e o mRNA da TP53 se encontravam respetivamente 
sobreexpresso (P=0.007) e subexpresso (P=0.016), na linha celular FG-2 comparativamente à 
linha celular HKC-8. Estudos adicionais realizados na linha celular FG-2 demonstraram que 24 ou 
48 horas após a transfeção com um mímico do miRNA-1233, os níveis de expressão do mRNA 
da TP53 não se alteraram. Contudo, o miRNA-1233 pode atuar ao nível do mRNA da TP53, 
inibindo a tradução e levando à diminuição dos níveis proteicos da p53 em vez de levar à 
degradação do mRNA. Todavia, o miRNA-1233 poderá constituir um promissor alvo terapêutico 
dado o seu papel oncogénico em CCRcc. O uso de exossomas GE11+ carregados com um 
antagonista do miRNA-1233 poderá afetar o desenvolvimento tumoral de CCRcc, tornando-se 
numa nova abordagem terapêutica. 
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Abstract 
 
Renal cell carcinoma is the most common solid kidney cancer and comprises three major 
histological subtypes, being the clear cell Renal Cell Carcinoma (ccRCC) the most prevelant and 
aggressive one. ccRCC is frequently characterized by the loss, mutation or epigenetic silencing 
of the Von-Hippel Lindau tumor suppressor gene (VHL). VHL impairment and consequent 
Hypoxia Inducible Factor (HIF) accumulation induces a state of hypoxia in non-hypoxic 
conditions, responsible for the dysregulation of several pathways, including the epidermal 
growth factor receptor (EGFR) activation through the production of transforming growth factor 
α (TGFα). Additionally, studies demonstrated EGFR overexpression and an increase in the 
receptor’s stability in the cell membrane in ccRCC. Since ccRCC patients end up developing 
resistance to the therapies applied in the clinic, there is the need to develop new therapeutic 
strategies that overcome these therapy limitations. EGFR dysregulation could be the base for 
the development of new targeted therapies. Recently, the exosomes have emerged as promising 
therapeutic tools due to their engineering potential and ability to evade the immune system. 
These extracellular vesicles of 30 to 150 nm can mediate intercellular communication through 
the shuttle of bioactive molecules like proteins, DNA, and microRNAs (miRNAs). GE11 is a 
synthetic peptide that specifically binds EGFR and can be expressed in the membrane of 
exosomes, allowing a specific delivery. Ultimately, these extracellular vesicles can be loaded 
with RNA interference (RNAi)-based drugs, small interfering RNA molecules that control gene 
expression post-transcriptionally, allowing a more specific deliver and potent drug effect. 
Increasing evidence supports the involvement of miRNAs in VHL/HIF axis regulation, ultimately 
affecting EGFR-related pathways. MiRNAs are small non-coding RNAs, responsible for numerous 
genes regulation at a post-transcriptional level. Studies proven that HIF can be directly regulated 
by p53 through MDM2-mediated degradation. In silico approaches predicted p53 as a miRNA-
1233 target. Thus, miRNA-1233 could regulate p53 levels and consequent HIF responses-related 
to hypoxia, such as EGFR activation making him a promising therapeutic target in ccRCC. 
Therefore, the aim of this study is to evaluate the potential use of GE11-positive (GE11+) 
exosomes as a delivery vehicle for RNAi-based therapy in cancer cells overexpressing EGFR, using 
ccRCC as a model. In the present study, in vitro experiments were performed using a metastatic 
ccRCC cell line, FG-2, two normal proximal tubule epithelial renal cell lines, HKC-8 and HK-2 and 
a human embryonic kidney-derived cell line, HEK293T. According to our results, EGFR mRNA 
expression levels were higher in FG-2 cells when compared to HKC-8 cells (P<0.001). Moreover, 
tumor cells also presented higher protein levels of EGFR as well as higher phosphorylated levels 
 
xv 
 
when compared to normal cells. In addition, downstream signaling MAPK/ERK was 
overactivated since higher levels of ERK2 phosphorylated form were found in FG-2 cells 
comparing to HKC-8 cells. Taken together, these results highlight the importance of EGFR in 
ccRCC development and the potential use of an EGFR-based exosomes delivery system. 
Exosomes derived from HEK293T were engineered in order to express the GE11 peptide on their 
surface, labeled with a fluorescent dye and incubated with either HK-2 or FG-2 cell lines at 4°C 
or 37°C for 4 hours. After incubation at 4°C there was almost complete abrogation of exosomes 
internalization by both renal cell lines, suggesting that cells had to be biologically active in order 
for this process to occur. Regarding cells incubation with exosomes at 37°C, a higher percentage 
of FG-2 cells internalized GE11+ exosomes comparing to exosomes derived from HEK293T cells 
transfected with pDisplay, the control condition (97% and 92%, respectively, P<0.001). In 
addition, by analyzing the fluorescence intensity from FG-2 cells we observed that cells that 
internalized GE11+ exosomes had a 1.4 greater fluorescence intensity median comparing to 
control (P=0.001), suggesting that each cell uptakes more GE11+ exosomes, in an EGFR-
dependent manner. Concerning HK-2 cells, differences between the internalization of GE11+ 
exosomes and the control were not observed since their protein EGFR levels were lower when 
compared to FG-2 cells. Overall, there was a statistical significant difference between GE11+ 
exosomes uptake by the normal and tumor renal cell lines (22% and 97%, respectively, P=0.001). 
However, uptake differences of GE11+ exosomes were not exclusively due to different EGFR 
expression levels between normal and tumor renal cell lines, since there was a significant 
difference concerning the uptake levels in the control condition (19% and 92%, respectively, 
P<0.001). Overall, the use of GE11+ exosomes is a very promising new delivery system in ccRCC 
and probably in others EGFR-overexpressing tumors. Initial findings demonstrated that miRNA-
1233 was upregulated (P=0.007) whereas, TP53 mRNA was downregulated (P=0.016) in FG-2 
cells comparing to HKC-8 cells. Additional studies performed in FG-2 cells showed that 24 or 48 
hours after transfection with a miRNA-1233 mimic, TP53 mRNA expression levels did not change. 
However, miRNA-1233 can still target TP53 mRNA and lead to its protein levels downregulation 
through translation inhibition, instead of mRNA degradation. Nonetheless, miRNA-1233 
dysregulation and its potential oncogenic role in ccRCC makes it a new promising candidate for 
drug targeting. The use of GE11+ exosomes loaded with a miRNA-1233 antagonist could 
potentially affect ccRCC tumor development, becoming a novel therapeutic approach. 
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1. Introduction 
 
 
 
1.1 Molecular biology of cancer 
 
Cancer is an emergent public health issue. It is one of the leading causes of death worldwide [1]. 
According to GLOBOCAN 2012, the International Agency for Research on Cancer (IARC) online 
database, in 2012 there were an estimated 14.1 million new cases of cancer diagnosed 
worldwide (excluding non-melanoma skin cancer) and 8.2 million cancer-related deaths [2]. 
Over the past years, cancer burden has increased in economically developing countries as a 
result of population aging and growth. Additionally, certain lifestyles and cancer-promoting 
behaviors such as smoking, physical inactivity, and ‘westernized’ diets have also contributed to 
the ascending numbers [3]. Thus, by the year of 2030, GLOBOCAN estimates an astonishing 
increase of approximately 77% of new cancer cases per year and 13 million deaths worldwide 
[4]. 
Cancer development is a multifactorial and multistep process which includes the following 
stages: initiation, promotion and progression [5].  Cells are continuously exposed to different 
types of aggressions that ultimately, upon failure of cell repairing machinery, can lead to a 
genetic and/or epigenetic modification in the DNA. On the one hand, genetic alterations can 
include chromosomal rearrangements and translocations, deletions, insertions, amplification of 
certain genes and point mutations. Most of the times, these genetic alterations occur in the 
somatic cells of the individual, whereas cancer predisposition syndromes with inherited 
mutations remain rare events [6]. On the other hand, epigenetic changes are often related with 
focal increases and/or decreases in DNA methylation and alterations in histone post-
translational modifications [7]. Altered genes can be categorized in proto-oncogenes or tumor 
suppressor genes regarding their role in tumor initiation and development. The proto-
oncogenes encode proteins that regulate normal cellular growth and differentiation, while 
mutated versions of these genes are named oncogenes and only require mutation in one allele 
to act dominantly and promote carcinogenesis. The tumor suppressor genes encode proteins 
that normally suppress cellular proliferation and both alleles must be mutated to interfere with 
normal cell function [8, 9]. Moreover, additional mutations in genes involved in DNA repair, cell-
cycle control, angiogenesis and telomerase production are also needed [6, 8]. Overall, these 
alterations contribute to the transformation of a normal cell into neoplastic. Proteins affected 
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by these genetic alterations include growth factors and their receptors, kinase inhibitors, signal 
transducers and transcription factors. Subsequently, multiple events occur that result in the 
disruption of key cellular processes such as cell proliferation and apoptosis, which in turn leads 
to tumor growth [6]. In fact, cells become less sensitive to apoptotic signals, cell growth arrest 
and destruction by the immune system.  Furthermore, the self-sufficiency of these cells in 
growth factors provides them with greater proliferative capacity, angiogenesis and invasive 
potential. These characteristics combined with increased inflammation, genomic instability and 
metabolism dysregulation, are considered the Hallmarks of Cancer and, ultimately, favor tumor 
development, invasion and systemic dissemination [10, 11].  
However, cancer is no longer perceived as a cellular disease defined exclusively by genomic 
alterations. Nowadays, cancer is seen as an ecological disease involving a dynamic and complex 
interplay between malignant and non-malignant cells [12, 13]. This new approach emphasizes 
the role of tumor microenvironment (TME) in cancer niche formation and its importance 
through tumor initiation and development processes [14]. Recently, Barcellos-Hoff and 
colleagues proposed the division of cancer niche evolution into three phases: construction, 
expansion and maturation (Figure 1) [13].  
Figure 1 – Diagram elucidating the interdependent processes that can occur in cancer niche evolution 
(niche construction, expansion and maturation) in parallel with classical multistep carcinogenesis model 
(initiation, promotion and progression). During niche construction stromal cells contribute to the survival 
of transformed cells. Niche expansion supports tumor cell diversity and contributes to angiogenesis, and 
eventually matures into the tumor microenvironment. CAF, cancer-associated fibroblast; IMC, immature 
myeloid cell. Adapted from Barcellos-Hoff et al. [13]. 
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Briefly, niche construction consists in the interaction between activated stromal cells and 
normal cells, enabling transformed clone survival. Consequently, niche expansion generates 
secreted factors such as chemokines, cytokines, exosomes and other molecules that remodel 
local tissue concomitant with initiated clone expansion. In fact, one of the predominant methods 
of communication between cells is through the exchange of bioactive molecules like proteins 
and microRNAs that are transported inside of exosomes, defined as extracellular vesicles (EV). 
Then, the recruitment of both bone-marrow-derived cells (BMDCs) and resident cells (especially 
fibroblasts) drives niche maturation up to an established TME [13]. The TME is composed by 
numerous cell types that surround tumor cells and include cells of the immune system such as 
lymphocytes, macrophages, natural killer cells and others, endothelial cells, fibroblasts, 
mesenchymal stem cells (MSCs) and the extracellular matrix (ECM). Each of these components 
interacts with and influences malignant cells, ultimately promoting tumor development [15]. 
Overall, these considerations highlight the complexity behind tumor initiation and progression 
that comprise a multifactorial communication between different cell types.  
 
 
 
1.2 Renal Cell Carcinoma 
 
Renal cell carcinoma (RCC) is the most common solid kidney cancer, accounting for 2-3% of all 
adult malignancies and 90% of all kidney neoplasms [16]. Considered the most lethal urologic 
tumor, the RCC is responsible for more than 100 000 deaths worldwide each year, and with 
incidence and mortality rates increasing approximately 2% per decade [17, 18].  
Incidence and mortality rates of RCC also reflect a geographic variation (Figure 2). The highest 
incidence rates are observed in Northern America, Western Europe and Australia/New Zealand, 
whereas relatively low rates are observed in Africa and South-East Asia. The highest mortality 
rates are registered in Europe, mainly in the central and eastern countries, followed by the 
western and southern regions [19].  
The geographic disparity observed in RCC incidence rates worldwide can be attributed to 
differences in frequency of diagnostic imaging, access to health care, genetic inheritance and 
prevalence of certain lifestyle habits and/or environmental risk factors [20]. 
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Figure 2 – Distribution of incidence and mortality rates of kidney cancer by 100 000 habitants (GLOBOCAN 
2012, IARC [4]).  
 
RCC etiology has not yet been completely elucidated. However, epidemiologic studies revealed 
an association between certain lifestyles and disease development. In accordance with the 
European Association of Urology (EAU) there is a 3:2 predominance of new cases diagnosed in 
men over women, with peak incidence occurring between the age of 60 and 70 years old [21]. 
Established risk factors for RCC include smoking, obesity, hypertension, acquired cystic disease, 
family history of RCC, and exposure to various chemical compounds [22, 23]. In addition, alcohol 
consumption, diabetes and nutritional factors also seem to modulate RCC development but 
further studies are needed in order to clarify their association with the disease [20, 24].  
Currently, more than 50% of RCCs are detected incidentally as a consequence of non-invasive 
imaging examinations, such as computed tomography and magnetic resonance imaging, used to 
investigate non-specific symptoms and other abdominal diseases [21, 25]. This fact can be 
explained since the majority of renal masses remain asymptomatic until late stages of the 
disease [21]. Therefore, one-third of the patients are initially diagnosed with locally invasive or 
metastatic disease [25]. For patients diagnosed with localized RCC surgical intervention is the 
primary treatment choice [26]. However, despite being considered curative, recurrence still 
occurs in 20-40% of patients depending on the tumor stage and grade [27]. Moreover, surgery 
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alone has limited benefit in patients with metastatic disease, except for palliative reasons [18, 
26]. Until the past decade, treatment options for patients with metastatic RCC (mRCC) have been 
extremely limited since RCC is notoriously resistant to chemotherapy and radiotherapy [28, 29]. 
Prior to the use of anti-angiogenic target agents, systemic treatment options were limited to 
cytokine therapies (interleukin – IL-2 and interferon α– IFNα). However, these approaches have 
limited therapeutic benefits [30, 31]. In the past years, following the identification of various 
molecular pathways linked to RCC initiation and progression, targeted agents such as receptor 
tyrosine kinase inhibitors (TKI), vascular endothelial growth factor (VEGF) antibodies, and 
mammalian target of rapamycin inhibitors (mTORs) are now a crucial part of most therapeutic 
strategies for patients with mRCC [25, 26, 32]. Although mRCC patient’s outcome has improved, 
tumor cells eventually become resistant to the targeted therapies applied due to genetic and 
epigenetic changes but mainly through downstream activation of the signaling pathway 
targeted therapy site [33-35].  
 
 
 
1.3 Molecular biology of clear cell Renal Cell Carcinoma  
 
RCC is not a single-entity disease. Instead, consists of different morphologic subtypes with 
distinct genetic backgrounds [36]. According to the ISUP Vancouver Modification of WHO there 
are more than twenty-four RCC subtypes, being the clear cell, papillary (Type I and II) and 
chromophobe the most frequent ones [36, 37]. The clear cell Renal Cell Carcinoma (ccRCC) not 
only is the most common but also the most aggressive subtype, presenting intense vascularity 
and high expression of angiogenic factors [38, 39]. Although this tumor is mainly associated with 
sporadic cases, it was the uncommon hereditary form, linked to von Hippel-Lindau (VHL) gene 
mutation, that gave insight in the mechanism involved in this tumor development [40]. Indeed, 
the majority of sporadic and hereditary (VHL syndrome) ccRCC cases lacks functional VHL due to 
loss, mutation or hipermethylation of VHL gene [41].  
The tumor suppressor gene VHL is located on the short arm of chromosome 3 (3p25-p26) and 
deletions in this region, which often involves the whole short arm of chromosome 3, are 
observed in approximately 90% of all ccRCC [42]. VHL encodes a protein (pVHL) that is the 
substrate-specifying component of the multiprotein E3 ubiquitin ligase ECV (Elongins B and 
C/Cullin 2/pVHL). pVHL catalyzes the poly-ubiquitylation of prolyl-hydroxylated substrates for 
subsequent degradation via 26S proteasome [41]. One of the most important protein targets of 
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pVHL is the Hypoxia Inducible Factor (HIF) family of transcription factors: HIF1α, HIF2α and HIF3α 
[43]. Once expressed in the cell, HIFα dimerizes with the constitutive expressed subunit HIFβ to 
form an active heterodimeric HIF transcription factor, and this complex translocates to the 
nucleus.  Under normoxic conditions, HIFα subunits are hydroxylated and recognized by pVHL 
that mediates its proteasome degradation (Figure 3 A) [43, 44]. On the other hand, since one of 
the early molecular events of ccRCC is the loss of pVHL, HIF accumulates and binds to hypoxia-
responsive elements (HREs) located in the promoter/enhancer regions of numerous hypoxia-
inducible genes in order to initiate various adaptive responses to hypoxia in non-hypoxic 
conditions. These genes are involved in pathways responsible for angiogenesis (VEGF), 
proliferation (transforming growth factor α –TGFα, platelet-derived growth factor β –PDGFβ), 
glucose metabolism (glucose transporter 1 – GLUT1, phosphoglycerate kinase – PGK, and lactose 
dehydrogenase A – LDHA), erythropoiesis (erythropoietin – EPO) and metastasis (chemokine (C-
X-C motif) receptor 4 – CXCR4) (Figure 3 B) [39, 45, 46]. To date, over 70 genes have been 
validated as direct HIF targets, indicating the complex network triggered upon HIF activation 
[47].  One of the activated genes is TGFα, that like Epidermal Growth Factor (EGF), is involved in 
cellular proliferation induction by activation of the Epidermal Growth Factor Receptor 
(EGFR/ErbB/Her1) (Figure 3 C) [48]. The ErbB/HER family contains four tyrosine kinase receptors 
(TKR), the EGFR/ErbB1/Her1, ErbB2/Her2/Neu, ErbB3/Her3, and ErbB4/Her4 consisting of an 
extracellular ligand-binding domain, a single transmembrane domain, an uninterrupted tyrosine 
kinase domain, and a cytoplasmic tail [49]. These TKRs are able to form homo- or heterodimers 
upon ligand binding [50, 51]. Downstream ErbB signaling pathways include PI3K/AKT, 
MAPK/ERK, PLCγ, and signal transducers and activators of transcription (STAT). All of these 
pathways are interconnected and overlapping [52, 53]. Overall, they regulate apoptosis, cell 
cycle progression, cytoskeletal rearrangement, differentiation, development, immune 
responses and transcription regulation [54].  
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EGFR is a well-known TKR often dysregulated in several malignancies. EGFR overexpression has 
been described in head and neck, breast, bladder, prostate, kidney, non-small cell lung cancer 
and glioma tumors [50]. In RCC, EGFR overexpression has been associated with higher tumor 
grade and poor overall survival [55]. The pVHL is also responsible for activated EGFR turnover 
and further degradation in the proteasome, thus during ccRCC development this process could 
be compromised leading to an increase of EGFR protein levels [56]. Additionally, Zhou and 
colleagues observed that EGFR half-life in cells with functional pVHL was approximately 1 hour, 
whereas in cells VHL-defective EGFR half-life triplicated [57]. Also, it has been described that 
hypoxia upregulates EGFR and prolong its activation through retention in the endocytic 
trafficking [56].  
VHL loss and consequent increase in EGFR half-life and overproduction of TGFα, leads to the 
activation of different pathways in an autocrine and/or paracrine fashion. Collectively, these 
findings demonstrate the importance of EGFR-related pathways in ccRCC progression.  
Furthermore, VHL impairment and EGFR pathways dysregulation in ccRCC have been associated 
with altered levels of microRNAs (miRNAs), a class of small non-coding RNAs of 19 to 25 
nucleotides [58, 59]. Mature miRNAs result from a sequential processing that initiates at the 
Figure 3 – Signaling pathways involved in ccRCC pathophysiology. A) VHL pathway under normoxic 
conditions: pVHL targets HIFα for proteasome degradation. B) VHL pathway under hypoxic conditions: 
VHL loss leads to HIFα accumulation in the nucleus and consequent binding of transcription factors, which 
trigger hypoxic responses. C) EGFR pathways activation by TGFα and its physiologic consequences. 
Adapted from Dias et al. 2013 [58]. 
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nucleus with the transcription of a primary RNA (pri-miRNA) by RNA polymerase II [60]. The pri-
miRNA is processed by two RNase III endonucleases, Drosha and Dicer, members of the 
Argonaute family. First, Drosha creates a pre-miRNA that is then exported to the cytoplasm and 
cleaved by Dicer into a mature 22 base pair double-stranded miRNA [61]. The mature miRNA is 
incorporated into the RNA-induced silencing complex (RISC), becoming functional [62]. MiRNAs 
are then able to bind to complementary sequences in the 3’ untranslated regions (3’ UTR) of 
their target mRNAs and induce mRNA degradation or translation repression, thus regulating 
several biological processes including cell mobility, differentiation, proliferation and apoptosis 
[63, 64]. Moreover, it has been shown that miRNAs are aberrantly expressed in cancer, and they 
have been considered a novel class of oncogenes or tumor suppressor genes [65]. OncomiRNAs 
are known to downregulate tumor suppressor genes, and have been reported to be 
overexpressed in multiple miRNA-profiling studies performed in different tumor models [65]. 
Whilst tumor suppressor miRNAs are responsible for downregulating oncogenes, and are mostly 
underexpressed in cancer [65, 66]. Some studies, mainly array-based ones, have demonstrated 
that a considerable number of miRNAs are dysregulated in ccRCC, and a few have been 
associated with altered signaling pathways in this malignancy [59, 67-69].  
In ccRCC, the crucial VHL/HIF/EGFR axis can be regulated by p53 action, since MDM2 (an E3 
ubiquitin–protein ligase) mediates HIFα degradation [70]. Additionally, it has been hypothesized 
that p53 levels could be regulated by miRNA-1233, becoming a potential central key player in 
the regulation of these signaling pathways (Figure 4) [58]. Recent studies developed by Dias and 
colleagues showed that various miRNAs were dysregulated in ccRCC, one of which miRNA-1233 
[71]. MiRNA-1233 levels were upregulated in plasma samples of ccRCC patients when compared 
to healthy subjects. Moreover, higher levels of this miRNA correlated with tumor grade and 
metastatic disease, suggesting the importance of miRNA-1233 in ccRCC dissemination [71]. 
Information concerning miRNA-1233 function is scarce. MiRNA-1233 is located on chromosome 
15q14 and was classified as an oncomiRNA for the first time by Wulfken and colleagues. They 
have confirmed upregulated levels of miRNA-1233 in serum samples of RCC patients compared 
to healthy controls [72]. Collectively, these findings demonstrate that miRNA-1233 could be a 
promising candidate to be targeted in ccRRCC. Furthermore, using in silico analysis Wulfken and 
colleagues found several potential targets for miRNA-1233, some of which are tumor suppressor 
genes, including TP53 [72]. The p53 transcription factor (encoded by TP53) is a key regulator of 
various signaling pathways tumor suppressor-related including: cell-cycle arrest, DNA repair, 
senescence, hypoxia-induced apoptosis, inhibition of angiogenesis and vascularization, among 
others [73]. In fact, p53 is known to limit tumor vascularization in three different ways: 1) 
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increasing anti-angiogenic factors production such as thrombospondin-1; 2) directly inhibiting 
HIF by targeting the HIF1α subunit for MDM2-mediated ubiquitination and proteasome 
degradation; and 3) negatively regulating the expression of genes encoding pro-angiogenic 
factors like VEGF [70, 74, 75].  These findings indicate that p53 regulates HIF-related pathways. 
In tumor cells p53 is often downregulated, amplifying the normal HIF-dependent responses to 
hypoxia. This is achieved through production of VEGF and TGFα, contributing to the angiogenic 
switch activation and to the EGFR-related pathways activation, respectively. Taken together, in 
a ccRCC context, high levels of miRNA-1233 could lead to p53 downregulation, ultimately 
promoting a continuous state of hypoxia, cell survival, cell proliferation and angiogenesis.  
In recent years, the increasing knowledge of the pathways involved in ccRCC initiation and 
progression has allowed the development of promising targeted therapies. The implication of 
certain genes such as VHL, HIF1α, EGFR and VEGF in ccRCC carcinogenesis led to the 
development of targeted therapies that can fall in two categories: TKI and monoclonal 
antibodies. TKI are small molecules that can target  a wide range of TKR such as sorafenib 
(Nexavar®) and sunitinib (Sutent®), they can be angiogenesis inhibitors for example axitinib 
(Inlyta®) and pazopanib (Votrient®), and also inhibitors of mammalian target of rapamycin 
(mTOR), for instance temsirolimus (Torisel®) and everolimus (Afinitor®). Additionally, antibodies 
Figure 4 – Proposed model of miRNA-1233 role during ccRCC development according to the results 
obtained by Dias et al. [71]. 
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like bevacizumab (Avastin®) can be used to inhibit angiogenesis by targeting VEGF [21]. 
However, a subset of patients (approximately 25%) do not experience any clinical benefit from 
these targeted therapies [33]. Moreover, in the majority of cases, patients initially respond to 
therapy but end up developing resistance after 5 to 11 months upon treatment, leading to 
cancer progression [34]. These observations highlight the importance of developing new 
therapeutic approaches in order to overcome therapy limitations currently faced in the clinic. 
Over recent years, many groups have focused their research in the discovery and development 
of new therapeutic strategies. As a result, a new promising specific delivery system has been 
identified: the exosomes [76]. 
 
 
 
1.4 Exosomes 
 
The best characterized EVs are the exosomes, ranging in size from 30 to 150 nm in diameter 
[77]. Exosomes are derived from the endolysosomal pathway and are formed within 
multivesicular bodies (MVBs), being released by cells upon fusion of MVBs with the plasma 
membrane  [77].  Most cell types produce exosomes, including tumor cells, and release them 
into the interstitial space, which ultimately enter circulation [78]. Therefore, exosomes can be 
found in different body fluids such as blood, saliva, urine, breast milk, amniotic fluid, ascites, 
cerebrospinal fluid, bile, and semen [77, 79]. This type of extracellular vesicles is enriched in 
cholesterol, sphingomyelin and ceramide as well as lipid-raft associated proteins [78, 80]. 
Proteomic studies showed that nearly all exosomes, regardless of the cell type from which they 
originate, contain a similar membrane composition. However, the exosomal lumen is 
determined by the cell type of origin and includes proteins, DNA and RNAs (mRNAs, miRNAs and 
other non-coding RNAs) [81, 82].  
Numerous studies have tried to identify the role of exosomes both in normal and pathological 
conditions [83]. Regarding the exosomes role in the immune system, it is known that they can 
trigger an immune response through T-cell activation either by a direct antigen presentation or 
by an indirect presentation through transfer of antigenic peptides to antigen-presenting cells 
[84, 85]. In an infectious disease context, pathogen-released exosomes are known to carry 
specific virulence factors that contribute to spread the infection [86, 87]. As a consequence, 
exosomes can either expand or contain the infection, hence being beneficial for the pathogen 
or the host. Exosomes were also proven to be involved in the normal development of the 
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nervous system and in its physiology, including synaptic plasticity [88]. Though, they were also 
associated with the generation and progression of many neurodegenerative diseases since they 
are able to shuttle toxic agents like misfolded proteins from unhealthy neurons to neighboring 
cells [89]. For instance, amyloid-β-derived peptides and α-synuclein, respectively linked to 
Alzheimer’s and Parkinson’s diseases [90, 91].  
However, it is in the field of cancer that exosomes have been extensively studied. Since the 
exosomal lumen reflects the content of the cell from which they originate, several studies have 
focused on their potential use as a diagnostic or prognostic tool. Exosomes provide means for a 
liquid biopsy that is minimally invasive. Indeed, as demonstrated by Melo and colleagues, 
exosomes derived from pancreatic cancer patients serum were positive for glypican-1 (GPC1) 
and able to distinguish healthy subjects and patients with a benign pancreatic disease from 
patients with early- and late-stage pancreatic cancer [92]. Furthermore, due to exosomes 
intrinsic ability of horizontal cargo transfer and high stability in circulation, they can interact with 
neighboring or distant cells and phenotypically reprogram recipient cells [93]. There are three 
main possible mechanisms of intracellular communication by exosomes (Figure 5) [35]. First, 
exosomal membrane proteins can interact with receptors in a target cell and activate different 
signaling pathways. Second, proteases in the extracellular space can cleave exosomal membrane 
proteins, leading to a cleaved fragment-target cell surface receptor interaction. This mechanism 
also activates intracellular signaling. Finally, exosomes can fuse with the target cell membrane 
 
Figure 5 – Possible mechanisms of exosome-target cell interaction. A) Interaction between exosomal 
membrane proteins and target cell receptors leads to intracellular signaling activation. B) Interaction 
between an ectodomain, formed after protease cleavage of exosomal membrane proteins, and target cell 
receptors also leads to signaling pathways activation. C) Exosomes fusion with the recipient cell 
membrane and content release to the intracellular space. Adapted from Adem et al. [35]. 
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and release their content, such as mRNAs and miRNAs, which can alter gene expression and 
protein translation of the recipient cell [78].  
Recently, various studies have showed the role of exosomes in tumor initiation, through driving 
the formation of a pre-metastatic tumor niche [94]. Also, increasing evidence demonstrates that 
tumor-secreted exosomes are able to stimulate tumor progression through different manners. 
It has been shown that exosomes can promote immune escape by modeling T cell activity and 
are able to regulate the hematopoyetic system, including lineage-specific differentiation of bone 
marrow precursors and dendritic cell (DC) function [95-98]. Their ability to induce cell 
proliferation and angiogenesis, contributing to tumor progression has also been established [99, 
100]. Additionally, tumor-derived exosomes containing specific factors can stimulate matrix 
metalloproteinase expression in fibroblasts and consequently promote matrix remodeling and 
ultimately facilitate tumor invasion and metastasis [101]. 
Despite latest findings and intensive efforts, the exosomes role in both normal and pathological 
conditions remains poorly understood. Further investigation is needed in order to clarify the 
precise way these extracellular vesicles can mediate cell-to-cell communication and affect the 
initiation and development of such a complex and heterogeneous disease like cancer. 
 
 
 
1.5 Exosomes-based therapy  
 
Exosomes have been explored for usage in therapy of a wide range of diseases. Numerous 
studies have demonstrated the possibility of using exosomes as vaccines for allergic or infectious 
diseases, and its applicability in autoimmune diseases treatment [102, 103]. Additionally, these 
extracellular vesicles are being extensively studied in cancer-related therapeutics. More 
specifically, exosomes are being used to either increase innate and adaptive immune responses 
against the tumor or to deliver therapeutic agents in a cancer-specific way [102].  
Regarding the use of exosomes in immunotherapy, patient-specific exosomes secreted by DC 
(dexosomes) can be loaded with tumor antigen-derived peptides and used as a vaccine to 
generate antitumor immune responses [104]. Phase I clinical trials using dexosomes in the 
treatment of metastatic melanoma and advanced non-small cell lung cancer showed that 
dexosome immunotherapy was feasible, safe, efficient in induction of both innate and adaptive 
immune responses, promoted disease stabilization increasing long-term survival in several 
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patients [105, 106]. A phase II clinical trial is currently on going for the treatment of non-small 
cell lung cancer with a dexosome-based vaccine [107]. Moreover, ascites-derived exosomes 
from colorectal cancer patients were also shown to be safe, nontoxic, and tolerable when used 
as a cancer vaccine. Furthermore, in advanced colorectal cancer patients when combining 
ascites-derived exosomes with granulocyte-macrophage colony-stimulating factor (GM-CSF) it 
was possible to efficiently induce potent antigen-specific antitumor immunity [108]. Even 
though major advances have been made in recent years, it should be noted that the application 
of exosomes as a cancer vaccine requires further research in order to completely clarify the 
mechanisms underlying this sort of approach, and more importantly, to standardize procedure 
methods.  
More recently, exosomes have been seen as an alternative in vivo delivery system to other 
therapeutic nanoparticles such as liposomes and polymers [109-111]. The intrinsic ability of 
exosomes to interact and modulate recipient cells through the shuttle of small molecules and 
also their high stability in circulation makes them an extremely promising candidate to an in vivo 
delivery of therapeutic agents [35, 112]. In fact, a phase I clinical trial is investigating the ability 
of plant-derived exosomes to deliver curcumin to normal and colon cancer tissue, since previous 
studies demonstrated that curcumin has a strong inhibitory effect on the growth of colon cancer 
cell lines by inhibiting mTOR signaling pathway [113, 114].  
Figure 6 – Emerging exosome-based strategies for cancer therapy. A) Immunomodulatory effects of 
exosomes can include antigen transfer and presentation to T cells (anticancer vaccines). B) Exosomes can 
be engineered to express certain cell type-specific ligands present on their surface by expressing plasmid 
fusion constructs comprising targeting ligands fused to extracellular vesicle transmembrane proteins. 
Drug loading can be achieved either endogenously (for example by overexpressing a miRNA in source 
cells) or exogenously (co-incubation or through electroporation). Finally, after collection and purification, 
exosomes can be tested in in vitro or in vivo. Adapted from Andaloussi et al. [115]. 
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In order to take full advantage of RNA drugs, an efficient, tissue-specific and non-immunogenic 
delivery technology must be developed. Exosomes are the most qualified candidates so far due 
to their biocompatibility, the fact they are immunologically inert if derived from appropriate 
cells, and able to protect sensitive drug molecules such as RNA, enhancing drug solubilization 
and surpassing the blood-brain barrier [76, 115]. In addition, they are natural RNA carriers 
making them a valuable tool for RNA interference (RNAi) delivery. RNAi is a phenomenon in cell 
biology whereby small RNA molecules (small interfering RNA (siRNA) and miRNA) control gene 
expression post-transcriptionally [115, 116].  
Alvarez-Erviti and colleagues were the first to provide evidence of the RNA-transporting capacity 
of exosomes [117]. In their study, DC-derived exosomes expressing Lamp2b, an exosomal 
membrane protein that reduces immunogenicity, fused to the neuron-specific RVG peptide 
were loaded with BACE (a therapeutic target in Alzheimer’s disease, since it is involved in β-
amyloid plaque formation) siRNA. These engineered vesicles were injected in mice and the 
siRNA was delivered specifically to the brain. Consequently, decreased BACE gene expression 
was observed in neurons, microglia and oligodendrocytes [117]. Regarding the use of exosomes 
containing exogenous miRNAs, these molecules can fall in two main categories: miRNA mimics 
or antagomiRNAs [118]. In order to restore the tumor suppressor levels of a certain miRNA, 
synthetic miRNA-like molecules called miRNA mimics can be used. MiRNA mimics are small, 
chemically modified (2′-O-methoxy) RNA duplexes that are processed into single-strand form 
inside the cells and loaded into RISC to achieve the downstream inhibition of the target mRNAs 
[118, 119]. OncomiRNAs, often overexpressed in tumor cells, can be inhibited using various 
synthetic modified antisense oligonucleotides such as anti-miRNA oligonucleotides (AMOs), 
locked nucleic acid (LNA) anti-miRNAs, miRNA sponges, miRNA masks, and small-molecule 
inhibitors of miRNAs [118, 120]. Since miRNAs regulate several cellular processes and are often 
dysregulated in cancer cells, agents that modulate miRNA activity could potentially produce 
cancer-specific effects [65]. The combination of engineered exosomes with RNAi-based therapy 
could become a new therapeutic approach for cancer treatment [76]. Indeed, Ohno and 
colleagues demonstrated the ability of GE11 positive (GE11+) exosomes to deliver a miRNA let-
7a mimic to breast cancer cells in vivo [121]. They engineered exosomes in order to express a 
fusion protein on their membranes, using the PDGF Receptor (PDGFR) transmembrane domain 
to anchor the protein to the exosomal membrane and expose the GE11 peptide to the 
extracellular space. The GE11 is a synthetic peptide that binds specifically to EGFR and is 
markedly less mitogenic than EGF [122]. In this study, breast cancer cells internalized the 
engineered exosomes through an EGFR-dependent mechanism. Additionally, miRNA-let-7a, a 
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tumor suppressor miRNA frequently downregulated in breast cancer, was introduced in GE11+ 
exosomes and used to treat an orthotropic breast cancer model in RAG2-/- mice [123].  This 
treatment resulted in an efficient delivery of GE11+ exosomes cargo to breast cancer cells with 
consequent tumor growth suppression and no major organ damage was detected in the injected 
mice [121].  Overall, Ohno and colleagues showed that GE11+ exosomes could be used as a new 
drug delivery system in an EGFR-overexpressing cancer model. 
It is known that EGFR is frequently overexpressed in a wide range of human tumors of epithelial 
origin including renal malignancies such as ccRCC [124]. Also, ccRCC patients end up developing 
resistance to chemotherapy, radiotherapy and to the targeted therapies used in ccRCC 
treatment [34, 35]. Hence, the development of new therapeutic approaches, as promising as 
this exosome-based one, are crucial to overcome limitations currently faced in this malignancy 
treatment. Collectively, these studies emphasize the potential use of engineered exosomes for 
the delivery of RNAi drugs like miRNA mimics or antagonists and its application in nanomedicine. 
Therefore, elucidating the mechanisms subjacent to ccRCC initiation and progression like the 
EGFR dysregulation and the potential involvement of miRNA-1233 in p53/HIF/EGFR pathways 
will contribute to the development of a new strategy for ccRCC treatment based on GE11+ 
exosomes, ultimately loaded with a miRNA-1233 antagonist.   
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2. Objectives 
 
 
2.1 Main Objective 
 
Study the potential applicability of GE11+ exosomes as a promising RNAi therapy delivery vehicle 
in ccRCC. 
   
 
2.2 Specific Objectives 
 
 In vitro characterization of EGFR and ERK pathway activation in a normal proximal tubule 
epithelial renal cell line and in a metastatic ccRCC cell line. 
 In vitro characterization of miRNA-1233 and TP53 mRNA expression levels in a normal 
proximal tubule epithelial renal cell line and in a metastatic ccRCC cell line.  
 Analysis of the functional association between miRNA-1233 and TP53 mRNA in a 
metastatic ccRCC cell line. 
 Production of engineered exosomes that display a synthetic EGFR ligand, the GE11 
peptide, on the membrane. 
 In vitro characterization of the uptake levels of GE11+ exosomes by a normal proximal 
tubule epithelial renal cell line and a metastatic ccRCC cell line. 
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3. Material and Methods 
 
 
3.1 Cell lines  
 
For this study, four cell lines were used: HEK293T, HKC-8, HK-2 and FG-2. HEK293T cell line is 
derived from human embryonic kidney cells and has an epithelial morphology.  Both HKC-8 and 
HK-2 are immortalized proximal tubule epithelial cell lines derived from normal adult human 
kidney. FG-2 is classified as a human kidney metastatic clear cell carcinoma cell line. 
To start cell culture a cryopreserved vial of each cell line used in this study was thawed. The 
HEK293T and FG-2 cell lines were maintained in RPMI 1640 (1X) medium (Gibco®), 
supplemented with 10% of FBS (Fetal Bovine Serum) (Gibco®), and 1% penicillin-streptomycin 
(Gibco®). The HKC-8 and HK-2 cell lines were kept in DMEM/F12 medium (Gibco®), 
supplemented with 10% of FBS (Gibco®), ITS (Insulin-transferrin-selenium) (Sigma-Aldrich), EGF 
(Sigma-Aldrich), hydrocortisone (Sigma-Aldrich), and 1% penicillin-streptomycin (Gibco®). All 
cell lines were maintained in a 5% CO2 incubator at 37°C.  
 
 
3.2 Plasmids propagation 
 
The plasmids used in the present study were: pDisplay and pDisplay-GE11, kindly provided by 
Doctor Shin-ichiro Ohno from Tokyo Medical University, Japan, and mCherry kindly given by 
Doctor Carlos Reguenga from Porto’s Medical School. The propagation of the plasmids was 
achieved by transforming the following competent bacteria NZYstar competent cells (nzytech). 
To extract and purify the plasmids of interest the kit NucleoBond® Xtra Midi (Machery-Nagel) 
was used according to the manufacturer’s protocol. The DNA concentration and purity related 
to each plasmid were measured at 260 and 280 nm using the NanoDrop® ND-1000 
spectrophotometer.  
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3.3 Transfections 
 
Regarding HEK293T cell line transfection the plasmids used were: pDisplay, pDisplay-GE11, and 
mCherry. HEK293T cell line was transiently transfected separately with each of the three DNA 
plasmids mentioned above (2µg DNA/5 × 105 cells) in adherent cells, using Invitrogen 
Lipofectamine® 2000 (Invitrogen) according to the manufacturer’s instructions. 
The FG-2 cell line was seeded in a 24-well plate with a confluence of 1.5 × 105 cells per well. Cells 
were transfected with a scrambled sequence (kindly given by Doctor Germana Zaccagnini from 
IRCCS-Policlinico San Donato, Italy) or with miRVana® miRNA-1233 mimic (has-miR-1233-3p, 
MC13610, Applied Biosystems®), both at a final concentration of 60nM, using ScreenFect®A 
(InCella) transfection reagent, according to the manufacturer’s instructions. 24 or 48h after 
transfection, cells were trypsinized and both mRNA and miRNA were isolated and purified as 
previously described for further analysis by real-time PCR of miRNA-1233, RNU-6B, TP53 and 
B2M levels. This experience was performed three times. 
  
 
3.4 Exosomes production and isolation 
 
HEK293T cells were grown for 72h in FBS-depleted exosomes RPMI media. Exosomes were 
isolated from cells supernatant. The medium was initially centrifuged at 12 000 rpm for 10 min 
and then filtered through a 0.22 μm filter (GE Healthcare Whatman™). Next, the exosomes were 
pelleted via overnight ultracentrifugation at 100 000 x g and 4°C using the Optima™ L-80 XP 
ultracentrifuge, Beckman Coulter, and the rotor SW 41.  
 
 
3.5 Western-blot 
 
HKC-8, HK-2 and FG-2 cell lines were plated in a 6-well plate (5 × 105 cells per well). Cells were 
washed with PBS (1X) (pH 7.4) (Fisher BioReagents™) and lysed with RIPA buffer (amresco) 
supplemented with protease inhibitor cOmplete (Roche®) and phosphatase inhibitor 
phenylmethanesulfonyl fluoride (Sigma-Aldrich). The cell lysates were incubated in ice for 30 
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min following a 30 min centrifugation at 17 000 x g and 4°C. Subsequently, total protein 
concentrations in the supernatant were determined using an adaptation to the Lowry’s method 
(DC™ Protein Assay Reagent, BIO-RAD®) according to the manufacturer’s instructions. For 
western-blot analyses 15μg proteins were separated by 10% (w/v) sodium dodecylsulphate 
(SDS)-polyacrylamide gel electrophoresis. The molecular weight estimation of the obtained 
bands was made using Precision Plus Protein™ Dual Color Standards (BIO-RAD®). The separated 
proteins were transferred onto nitrocellulose membranes 0.2μm (GE Healthcare®) using a wet 
electrophoretic transfer for 2h at 100V. The membrane was blocked for 1h at room temperature 
with 5% non-fat dry milk in PBS/0.1% Tween 20. The following primary antibodies were added 
and incubated overnight on a shaker at 4°C: anti-EGFR (dilution 1:1000, Cell Signalling®), anti-
pEGFR (dilution 1:500, Cell Signalling®), anti-ERK1/2 (dilution 1:1000, Cell Signalling®), anti-
pERK1/2 (dilution 1:1000, Cell Signalling®), and anti-β-actin (dilution 1:5000, Sigma-Aldrich). 
Afterwards, horseradish peroxidase (HRP)-conjugated secondary antibodies (dilution 1:10 000, 
Cell Signalling®) were incubated for 1h at room temperature.  
Regarding HEK293T-related western-blots, protein extraction from HEK293T cells followed the 
procedure above mentioned while for protein isolation from HEK293T exosomes, the exosomes 
pellet were lysed in 8 M urea and 2.5% SDS, incubated in ice for 30 min following a 30 min 
centrifugation at 17 000 x g and 4°C. After protein isolation and quantification as previously 
described, 15μg proteins from HEK293T cells and 20μg proteins from HEK293T exosomes were 
separated by 15% (w/v) SDS-polyacrylamide gel electrophoresis. The separated proteins were 
transferred onto Polyvinylidene Difluoride (PVDF) membranes 0.2μm (BIO-RAD®) using a wet 
electrophoretic transfer for 1h at 65V and 4°C. The membranes were blocked for 1h at room 
temperature with 5% non-fat dry milk in PBS/0.1% Tween 20. Next, the following primary 
antibodies were added and incubated overnight on a shaker at 4°C: anti-c-Myc (dilution 1:200, 
9E10, Santa Cruz Biotechnology®), anti-hemagglutinin (anti-HA) (dilution 1:1000, Sigma-Aldrich) 
and anti-β-actin (dilution 1:5000, Sigma-Aldrich). Then, blots were incubated for 1h at room 
temperature with the respective HRP-conjugated secondary antibodies (dilution 1:10 000, Cell 
Signalling®).  
All washes after antibody incubations were done on an orbital shaker, four times at 10 min 
intervals, with PBS/0.1% Tween 20. To finalize, all membranes were incubated with Clarity™ 
Western ECL Substrate (BIO-RAD®), according to the manufacturer’s recommendations, for 
visualization on a ChemiDoc machine using ImageLab (BIO-RAD®) or development using GE 
Healthcare Amersham™ Hyperfilm™ ECL. 
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3.6 Immunofluorescence 
 
HEK293T cells were plated 24h prior to the transient transfection with pDisplay-GE11 plasmid in 
a 24-well plate (1.1 × 105 cells per well). Each well had been previously coated with a coverslip 
and treated with a solution of 10% Poly-L-Lysine (Sigma-Aldrich) for 1h at room temperature. 
The cell medium was replaced 8h after transfection. The immunofluorescence protocol was 
started 36h after transfection and cells were washed with cold PBS (1X) (Fisher BioReagents™) 
and fixed in 4% paraformaldehyde (PFA) (Sigma Aldrich) for 15 min at room temperature. 
Afterwards, a quenching solution of glycine 1M was added to cells. The blocking was performed 
by incubating cells for 45 min with a solution of 10% FBS (Gibco®). Cells were incubated 
overnight with the primary antibody anti-c-Myc (dilution 1:200, 9E10, Santa Cruz 
Biotechnology®) or anti-HA (dilution 1:500, Sigma-Aldrich) at 4°C. Next, cells were incubated for 
45 min with the secondary antibodies anti-IgG mouse or anti-IgG rabbit Alexa-Fluor® 488 
(dilution 1:1500, Invitrogen®). All the washing steps were made using PBS (1X) (Fisher 
BioReagents™) and by incubating cells for 5 min at room temperature more than once. Then, 
coverslips were mounted using a drop of fluoroshield mounting medium with DAPI (abcam®). 
The coverslips were sealed with nail polish to prevent drying and movement under microscope 
and samples were kept at 4°C protected from light until observation using laser scanning 
confocal microscope Leica TCS SP5 II (Leica Microsystems, Germany). 
 
 
3.7 Transmission electron microscopy immunogold  
 
The engineered exosomes produced by HEK293T cells were labeled and then visualized using 
transmission electron microscopy (TEM) according to Théry et al. [125]. Briefly, the pellet of 
exosomes obtained after ultracentrifugation was resuspended in 100µL of 2% PFA. Next, 5μL of 
this mixture was transferred onto Formvar-carbon coated electron microscopy grids (Electron 
Microscopy Sciences). The membranes were incubated for 20 min. Grids were transferred to a 
50µL drop of saline solution with the sample membrane side facing down and were washed 
twice for 2 min. Afterwards, grids were moved to a 50µL drop of saline solution/Glycine 50mM 
for 3 min and were washed four times. Grids were blocked for 15 min in saline solution/BSA 5%. 
Then, samples were incubated for 45 min with the primary antibody at a final dilution of 1:20. 
For this step, grids were transferred to a 5µL drop of saline solution/BSA 1% with the primary 
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antibody anti-c-Myc (dilution 1:20, 9E10, Santa Cruz Biotechnology®) or CD81 (dilution 1:20, 
abcam®). Next, grids were washed in a 50µL drop of saline solution/BSA 0.1% for 3 min for a 
total of six washes. The secondary antibody (anti-mouse gold or anti-rabbit gold) (dilution 1:20, 
abcam®) was diluted in saline solution/BSA 0.5% at a final volume of 5µL and incubated for 30 
min at room temperature. Grids were washed in a 50µL drop of saline solution/BSA 0.5% for 3 
min for a total of six washes. Grids were transferred to a 50µL drop of 1% glutaraldehyde for 5 
min before transferring to a 50µL drop of distilled water for 2 min. This was repeated 7 times for 
a total of 8 water washes. To contrast samples, grids were transferred to a drop of uranyl acetate 
for 5 seconds. Grids were left to dry and observed with JEM 1.011 transmission electron 
microscope at 80 kV. 
 
 
3.8 Exosomes staining  
 
Exosomes were labeled with the green fluorescent dye PKH67 (Sigma-Aldrich) according to the 
manufacturer’s recommendations. Briefly, the pelleted exosomes obtained from HEK293T 
culture media were resuspended in 1ml Diluent C, and 4μl PKH67 was diluted in another 1ml 
Diluent C. These two solutions were mixed gently for 5 min, after which 2ml 2% BSA was added 
to bind the excess dye. The mixture was subsequently ultracentrifuged overnight at 100 000 x g 
and 4°C and the final pellets were resuspended in complete medium. 
 
 
3.9 Flow cytometry 
 
In order to evaluate the uptake levels of the engineered fluorescent labeled exosomes by normal 
and tumor renal cell lines, flow cytometry was performed. FG-2 and HK-2 cells were plated in a 
12-well plate (2 x 105 cells per well). After 24h, the pellet of exosomes correspondent to one well 
of a 6-well plate was used to treat cells plated in three wells of a 12-well plate. Both cell lines 
were treated with the engineered fluorescent labeled exosomes for 4 hours at 37°C or 4°C. The 
experiment was performed in triplicates. 
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3.10  RNA extraction and cDNA synthesis 
 
Regarding HKC-8 and FG-2 cell lines, when the desired confluence was achieved (80-90%) cells 
were trypsinized, using 0.05% (w/v) trypsin-EDTA (1×) (Gibco®) and counted using a Neubauer 
chamber and Tripan-Blue dye (Gibco®). After counting, approximately two million cells were 
centrifuged for 3 min at 1200 rpm to form a pellet for mRNA or miRNA extraction and the 
remaining cells were kept in culture under the conditions above cited. This procedure was 
repeated ten times for each cell line.   
Total RNA extraction and purification was performed using the GeneJET™ RNA purification kit 
(Thermo Scientific®), according to the manufacturer’s instructions. After isolation, NanoDrop® 
ND-1000 spectrophotometer was used to determine RNA concentration and purity by 
measuring absorbance at 260 and 280 nm. The RNA samples were then used as templates for 
cDNA synthesis using the High-Capacity RNA-to-cDNA kit (Applied Biosystems®) in accordance 
with the manufacturer’s protocol.  
Regarding miRNA extraction and purification, GRS microRNA kit (Grisp®) was used according to 
the manufacturer’s instructions. After isolation, miRNA concentration and purity were 
measured at 260 and 280 nm using the NanoDrop® ND-1000 spectrophotometer. Then, the RNA 
samples served as templates for cDNA synthesis using the TaqMan®MicroRNA Reverse 
Transcription Kit (Applied Biosystems®) and sequence-specific stem-loop primers for miRNA-
1233, RNU-48 and RNU-6B.  
 
 
3.11  Real-time PCR relative quantification 
 
The mRNA and miRNA expressions were analyzed by quantitative real-time PCR, using a 
StepOneTMqPCR Real-Time PCR machine. Concerning mRNA analysis, each reaction contained 
1X Master mix (Applied Biosystems®), 1X specific probes for each transcript in study (TaqMan® 
Gene Expression Assays: EGFR: Hs01076078; TP53: Hs01034249, B2M (Beta-2-Microglobulin) 
Endogenous control: 4333766, Applied Biosystems®), and cDNA sample. B2M was used to 
normalize the results since it presents a constant expression level in the cell lines in study. 
Regarding miRNA analysis, each reaction contained 1X Master mix (Applied Biosystems®), 1X 
probes (TaqMan® microRNA Expression Assays: miRNA-1233: TM-002768, RNU-48: TM-001006, 
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RNU-6B: TM-001093, Applied Biosystems®), and cDNA sample. RNU-48 was used as endogenous 
control when comparing HKC-8 and FG-2 samples, whereas RNU-6B was used as endogenous 
control when comparing samples from FG-2 cells only (miRNA-1233 mimic experiments). These 
endogenous controls were chosen upon previous protocol optimization, in order to normalize 
the results since they are expressed in a constant manner.  
Data analysis was made using StepOneTM Sofware v2.2 (Applied Biosystems®) with the same 
baseline and threshold set for each plate in order to generate threshold cycle (Ct) values for all 
the mRNA or miRNAs in each sample. Each quantification was performed in duplicate and a 
negative control was included in all reactions.                                        
 
 
3.12  Statistical Analysis 
 
Statistical analysis of RNA quantifications and uptake levels of the engineered exosomes was 
performed using IBM®SPSS®Statistics software for Windows (Version 22.0). The 2-ΔΔCt method 
(Livak method) and the t’ Student test were used to evaluate the differences in the expression 
levels of the normalized mRNA and miRNA in study. The t’ Student test was also used to evaluate 
the uptake differences of the fluorescent labeled exosomes by the renal cell lines in study.  
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4. Results 
 
 
4.1  In vitro analysis of EGFR dysregulation in renal cell carcinoma 
 
In order to evaluate EGFR dysregulation in the renal cell lines in study, mRNA expression levels 
of EGFR were assessed and the results were represented as expression fold-change in figure 7. 
According to the data, FG-2 cell line presented a 3.14 fold-increase of EGFR mRNA expression 
levels when compared to the HKC-8 cell line (P<0.001).  
 
 
Moreover, total EGFR protein levels were analyzed, as represented in figure 8 A, and a 
correlation between mRNA expression levels and protein levels was observed. Therefore, FG-2 
cell line presented higher levels of total EGFR protein comparing to HKC-8 cell line. Furthermore, 
regarding EGFR phosphorylated levels at the site Y1068, data shows an overactivation of the 
receptor in FG-2 cells comparing to HKC-8 cells (Figure 8 B). In addition, according to the results 
represented in figure 8 C, ERK1/2 levels were similar in both cell lines. However, according to 
the data, the tumor renal cell line presented higher levels of phosphorylated ERK2, also known 
as p42, comparing to the normal renal cell line. Overall, these results indicate that EGFR is not 
only overexpressed but also overactivated in FG-2 cells which can lead to ERK2 overactivation.  
 
Figure 7 – Expression fold-change of EGFR mRNA levels between HKC-8 and FG-2 cell lines. Data is 
indicated as mean ± SEM. **, P<0.001.    
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4.2  Production of an EGFR-exosome targeted delivery system in HEK293T cell line 
 
To generate GE11+ exosomes a plasmid was used in which the backbone vector was the 
pDisplay™ (Figure 9). Proteins expressed from pDisplay™ are fused at the N-terminus to the 
murine Ig κ-chain leader sequence, which directs the protein to the secretory pathway, and at 
the C-terminus to the PDGFR transmembrane domain, which anchors the protein to the plasma 
membrane, displaying the peptide of interest to the extracellular side.  
Figure 8 – Western-blot representing EGFR and ERK1/2 activation in HKC-8 and FG-2 cell lines. A) Total 
EGFR protein levels, B) Phosphorylated levels of EGFR at Y1068 site C) Total and phosphorylated levels of 
ERK1/2. The β-actin levels were used to normalize samples in all experiments. 
ERK2 
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HKC-8 FG-2 
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HKC-8 FG-2 
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HKC-8 FG-2 
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Figure 9 – Diagram of the GE11 construct. Signal peptide Igκ-chain leader sequence; HA, hemagglutinin 
epitope tag (YPYDVPDYA); Linker, (GGGGS)x3; Myc, Myc epitope tag (EEKLISEEDL); platelet-derived 
growth factor receptor (PDGFR) transmembrane domain. 
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HEK293T cells were transiently transfected with the plasmids of interest pDisplay or pDisplay-
GE11. The plasmid mCherry was used as a transfection control (Figure 10). 
 
In order to evaluate the expression of the GE11 in HEK293T cells a western-blot was performed 
using anti-Myc or anti-HA antibodies (Figure 11 A and B, respectively). As expected, only 
HEK293T cells transfected with pDisplay-GE11 were positive for the Myc or HA tags. 
 
 
Regarding the immunofluorescence experiment, HEK293T cells were transfected with pDisplay-
GE11 and as a negative control non-transfected HEK293T were used. Non-permeabillized cells 
were incubated either with anti-Myc or anti-HA antibodies (Figure 12 A and B, respectively). In 
accordance with the western-blot results, only HEK293T cells expressing GE11 were positive and 
results were similar for both antibodies. 
A B C 
β-actin 
Myc tag 23 kDa 
β-actin 
HA tag 
A B 
42 kDa 42 kDa 
23 kDa 
Figure 10 – Transfection control of HEK293T cells with mCherry plasmid. A) bright field B) red channel C) 
merge. ZOE Fluorescent Cell Imager (BIO-RAD®). 
Figure 11 – Western-blot representing GE11 expression in HEK293T cells using A) anti-Myc antibody or 
B) anti-HA antibody. The β-actin levels were used to normalize samples in all experiments. 
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Figure 12 – Membrane-labeled HEK293T cells were detected when using A) anti-Myc or B) anti-HA 
antibodies, using confocal fluorescence microscopy. For both A) and B) diagrams: a) non-transfected 
HEK293T cells and c) HEK293T cells transfected with pDisplay-GE11, c’) zoom in from image c) and arrows 
point to the membrane labeling. b) and d) represent the negative controls, respectively of a) and c), in 
which cells were incubated only with the secondary antibody, Alexa-Fluor® 488. 
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Since HEK293T cells were expressing and correctly directing the protein of interest to the cell 
membrane, exosomes were then isolated and purified for further analysis. In order to evaluate 
the expression of GE11 in HEK293T-derived exosomes a western-blot using anti-Myc or anti-HA 
antibodies was performed (Figure 13 A and B, respectively). According to the data, only 
exosomes derived from HEK293T cells transfected with pDisplay-GE11 were positive for the Myc 
or HA tags. 
 
 
In order to assess if HEK293T-derived exosomes had the GE11 peptide displayed to the 
extracellular space transmission electron microscopy immunogold was performed. Samples 
were labeled either with anti-CD81 or anti-Myc antibodies and visualized using electron 
microscopy as represented in figure 14. According to the data, the method used to isolate and 
purify exosomes resulted in the visualization of bilayer nanoparticles raging in size 
approximately from 50 to 100 nm that were CD81 positive (Figure 14 A), which is consistent with 
exosomes characteristics. Exosomes derived from HEK293T cells previously transfected with 
pDisplay-GE11 were incubated with anti-Myc antibody and a membrane labeling was observed 
as represented in figure 14 C. As a negative control exosomes derived from non-transfected 
HEK293T were also probed with anti-Myc antibody and no labeling was observed as represented 
in figure 14 E.  
 
47 kDa 
23 kDa HA tag 
FLOT 1 FLOT 1 
Myc tag 
A B 
23 kDa 
47 kDa 
Figure 13 – Western-blot representing GE11 expression in HEK293T-derived exosomes using A) anti-Myc 
antibody or B) anti-HA antibody. The flotillin1 (FLOT1) levels were used to normalize samples in all 
experiments. 
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Figure 14 – Immunogold of HEK293T-derived exosomes. A) HEK293T exosomes incubated with CD81; B) 
HEK293T exosomes negative control: IgG anti-mouse gold; C) GE11+ exosomes incubated with anti-Myc; 
D) GE11+ exosomes incubated with IgG anti-mouse gold; E) non-transfected HEK293T-derived exosomes 
incubated with anti-c-Myc F) non-transfected HEK293T-derived exosomes incubated with IgG anti-mouse 
gold. 
 
 
 
4.3 Analysis of the uptake by renal cell lines of the engineered exosomes  
 
In figure 15 is represented total EGFR protein levels in the normal HK-2 and in the tumor FG-2 
renal cell lines. In accordance with the results, FG-2 cells presented higher levels of total EGFR 
protein when compared to HK-2 cells. Hence, further studies were performed in order to 
evaluate the engineered exosomes uptake levels by HK-2 and FG-2 renal cell lines. 
 
β-actin 
EGFR  
HK-2 FG-2 
42 kDa 
170 kDa 
Figure 15 – Western-blot representing EGFR expression in HK-2 and FG-2 renal cell lines. The β-actin 
levels were used to normalize samples in all experiments. 
 
30 
 
Exosomes derived from HEK293T cells transfected with pDisplay (control condition) or pDisplay-
GE11 were labeled with PKH67 dye (green) and added to cultures of FG-2 or HK-2 cells at either 
4°C or 37°C, for 4 hours. As represented in figure 16, at 4°C there was almost complete 
abrogation of exosomes uptake. Regarding HK-2 cells there was 1.7% uptake in the control 
condition and 0.0% uptake of GE11+ exosomes. Whilst in FG-2 cells there was 0.1% and 0.2% 
uptake in the control condition and after cells incubation with GE11+ exosomes, respectively. 
Concerning the uptake analysis of the engineered exosomes by the renal cell lines at 37°C (Figure 
16) a different pattern of uptake was observed, depending on the cell line in study. 
 
FG-2 cells 
FG-2 cells + exosomes control condition at 4°C  
FG-2 cells + exosomes control condition at 37°C  
HK-2 cells 
HK-2 cells + GE11
+
 exosomes at 4°C  
HK-2 cells + GE11
+
 exosomes at 37°C  
FG-2 cells 
FG-2 cells + GE11
+
 exosomes at 4°C  
FG-2 cells + GE11
+
 exosomes at 37°C  
HK-2 cells 
HK-2 cells + exosomes control condition at 4°C  
HK-2 cells + exosomes control condition at 37°C  
A B 
C D 
Figure 16 – Internalization levels of the fluorescent labeled engineered exosomes by HK-2 and FG-2 cell lines. 
A) and B) correspond to the uptake levels of exosomes derived from HEK293T cells transfected with pDisplay 
(control condition) after 4 hours incubation at 4°C or 37°C by HK-2 or FG-2 cell lines, respectively. C) and D) 
correspond to the uptake levels of GE11+ exosomes after 4 hours incubation at 4°C or 37°C by HK-2 or FG-2 
cell lines, respectively. Baseline settings were determined using a sample of each cell line that had not been 
treated. The percentages correspondent to the uptake levels of the engineered exosomes at 37°C are 
represented in each case. A representative experiment was used as an example. 
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Regarding HK-2 cells, despite the nature of the exosomes in study, the uptake levels remained 
similar (average levels were 19.7% and 22.2% for the control condition and GE11+ exosomes, 
respectively). Furthermore, as represented in figure 17 A, the median fluorescence intensity was 
the same whether looking at HK-2 cells incubation with exosomes derived from HEK293T cells 
transfected with pDisplay or pDisplay-GE11. Overall, no statistical significant differences were 
observed when comparing the uptake levels of GE11+ exosomes with the control condition in 
HK-2 cells. Conversely, for FG-2 cells, a statistical significant difference between the uptake of 
GE11+ exosomes (97.4%) and the control condition (91.8%) was observed (P<0.001). 
Additionally, as illustrated in figure 17 B, the median fluorescence intensity was approximately 
1.4 times greater (P=0.001) when comparing the uptake of GE11+ exosomes with the control in 
FG-2 cells.  
 
 
Figure 17 – Fluorescence intensity patterns of A) HK-2 cells and B) FG-2 cells after internalization of the 
engineered exosomes at 37°C for 4 hours. Events refer to cell counts that were normalized to mode. A 
representative experiment was used as an example. 
 
Moreover, according to the results, there was a statistical significant difference between the 
uptake of the exosomes derived from HEK293T cells transfected with pDisplay, the control 
condition, by the HK-2 and FG-2 cell lines, 19.2% and 91.8%, respectively (P<0.001). Finally, when 
comparing the uptake levels of GE11+ exosomes from both renal cell lines in study, there was a 
significant increase in the uptake by tumor cells rather than by normal cells (FG-2: 97.4% and 
HK-2: 22.2%, P=0.001). Representative images of the engineered exosomes uptake by FG-2 cell 
line, 4 hours after incubation at 37°C are illustrated in figure 18. 
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Figure 18 – Intracellular PKH67-labeled exosomes were detected in FG-2 cells using confocal fluorescence 
microscopy. Exosomes derived from HEK293T cells transfected with A) pDisplay (control) or B) pDisplay-
GE11, are represented in green.  
 
 
 
4.4 MiRNA-1233 and TP53 mRNA functional relationship in renal cell carcinoma 
 
In figure 19 A is represented the expression fold-change of miRNA-1233 levels in HKC-8 and FG-
2 cell lines. According to the results, there was a 9 fold-increase in the intracellular levels of 
miRNA-1233 in FG-2 cell line when compared to HKC-8 cell line (P=0.007).  In figure 19 B is 
represented the expression fold-change of TP53 mRNA in both cell lines in study and there was 
a 0.54 fold-decrease in expression in FG-2 cells comparing to HKC-8 cells (P=0.016).  
 
 
After miRNA-1233 and TP53 mRNA expression levels characterization the functional relationship 
of these two molecules was assessed in the tumor renal cell line. Therefore, FG-2 cells were 
either transfected with a scramble sequence or with miRVana® miRNA-1233 mimic. 24 and 48h 
B 
Control 
DAPI 
GE11 
DAPI 
A 
Figure 19 – MiRNA-1233 and TP53 mRNA intracellular levels fold-change between HKC-8 and FG-2 renal 
cell lines. Data is indicated as mean ± SEM. *, P<0.05.    
A B 
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after transfection, miRNA-1233 and TP53 mRNA expression levels were assessed as shown in 
figure 20 A and B, respectively. The overexpression of miRNA-1233 was successfully achieved 
and according to data there was an 843 and a 77 fold-increase in expression 24 (P<0.001) and 
48 hours (P=0.007) after transfection, respectively. Regarding TP53 mRNA expression levels 
upon miRVana® miRNA-1233 mimic transfection, as represented in figure 20 there were no 
statistical significant differences observed. 
 
 
 
 
    
Figure 20 – MiRNA-1233 and TP53 mRNA intracellular levels fold-change between FG-2 cell line A) 24 
hours after and B) 48 hours after transfection with a scramble sequence or with miRVana® miRNA-1233 
mimic. Data is indicated as mean ± SEM. *, P<0.05 and **, P<0.001. 
A 
B 
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5. Discussion 
 
ccRCC is the most common and aggressive histological subtype of all renal cell carcinomas, and 
it is characterized by the frequent loss, mutation or epigenetic silencing of VHL gene [38, 39, 41]. 
VHL impairment induces a state of hypoxia in non-hypoxic conditions trough HIF accumulation 
and consequent transcriptional activation of various genes involved in hypoxia-adaptive 
responses [45]. One of those responses include increased expression of TGFα, an agonist to 
EGFR, able to enhance the receptors activity and therefore promote tumor growth [126]. The 
tumor renal cell line used in the present study is an in vitro model of a VHL-defective cell line 
thus, EGFR and ERK1/2 downstream signaling pathway were evaluated. According to our results, 
EGFR mRNA expression levels were higher in the metastatic ccRCC cell line when compared to 
normal proximal tubule epithelial renal cell line. Moreover, tumor cells presented higher protein 
levels of EGFR as well as higher phosphorylated levels at the site Y1068 of the receptor when 
compared to normal cells. Behind this pathway dysregulation may be several factors including 
the increased translational efficiency of EGFR mRNA induced by HIF2α and the delayed turnover 
of the activated EGFR in VHL-defective ccRCC cells [127]. The increased EGFR half-life can be 
directly related with the loss of pVHL that targets the phosphorylated protein to proteasome 
degradation or due to HIF accumulation that suppresses the activated EGFR lysosomal-mediated 
degradation [55, 56]. After EGFR activation via the phosphotyrosine residue Y1068, Grb2 
adaptor protein is recruited and MAPK/ERK1/2 downstream signaling is activated [50, 128]. 
Indeed, our data also suggested an overactivation of MAPK pathway since higher levels of ERK2 
phosphorylated form were detected in tumor cells comparing to normal cells.  Once activated, 
ERK is able to translocate to the nucleus and activate various transcription factors, including Fos 
and STAT3 [129]. Ultimately, these activated transcription factors modify gene expression 
profiles that regulate cell proliferation and survival, resulting in cell growth induction [129]. 
Moreover, it has been shown that ERK1/2-MAPK can increase HIF1 transcription activity directly 
by phosphorylating HIF1α or by phosphorylating the p300/CBP co-activator [130, 131]. Taken 
together, VHL and HIF dysregulation, higher levels of TGFα, EGFR overexpression and 
downstream signaling activation contribute to a positive feedback loop that sustains an 
autocrine solicitation of proliferation and survival, contributing to tumor growth. In fact, recent 
studies have demonstrated that higher EGFR expression levels have been correlated with higher 
tumor grade and shorter survival in ccRCC patients [55, 132, 133]. Overall, these findings 
highlight the importance of EGFR in ccRCC development and progression.  
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Approximately one-third of all patients are diagnosed with metastatic disease due to the fact 
that ccRCC remains asymptomatic until late stages of the disease [21, 25]. Furthermore, this 
tumor is notoriously resistant to chemotherapy, radiotherapy and to the targeted therapies 
today applied in the clinic [28, 33-35]. Therefore, there is the need to develop new therapeutic 
strategies that overcome these therapy limitations. EGFR dysregulation could be the base of 
new targeted therapies development. It has been demonstrated that engineered exosomes that 
express a certain ligand on their surface will bind to a targeted cells receptor and deliver their 
content to the recipient cell [117]. The production of GE11+ exosomes is one good example. In 
the course of our study, an exosome-based delivery system was developed in which the peptide 
GE11 was facing to the extracellular space. It has already been proven that the GE11 peptide is 
able to bind specifically to EGFR, allowing an EGFR-dependent uptake by the targeted cells [121]. 
Ohno and colleagues demonstrated that the GE11+ exosomes internalization levels correlated 
with EGFR expression levels in different breast cancer cell lines. Additionally, after EGFR knock-
down in a breast cancer cell line, a decrease in GE11+ exosomes internalization levels was 
observed [121]. More importantly, they demonstrated that a GE11+ exosomes-based delivery 
system was viable in vivo, since GE11+ exosomes loaded with miRNA let-7a significantly 
suppressed tumor growth in an orthotropic breast cancer model in RAG2-/- mice. Concerning our 
experiments, the engineered exosomes were incubated with either the normal or tumor renal 
cell lines at 4°C. At this condition, the exosomes uptake was almost inexistent, suggesting that 
cells had to be biologically active in order for this process to occur. In addition, since low 
temperatures decrease membrane fluidity, at 4°C cell membranes become more rigid, possibly 
preventing exosomes uptake [134]. These results are in accordance with others that also 
performed incubation at 4°C of cells treated with fluorescently labeled exosomes  [134-136]. On 
the other hand, when cells were incubated at 37°C we were able to see exosomes accumulating 
inside of the cells. Several exosomes were located in the perinuclear region, suggesting that 
some might have followed the endocytic pathway [136]. Furthermore, when analyzing the 
uptake levels of the engineered exosomes by the tumor cell line we could see an increase of 
approximately 6% in the uptake of GE11+ exosomes comparing to exosomes derived from 
HEK293T cells transfected with pDisplay, the control condition. The difference between the 
engineered exosomes uptake is due to an EGFR-dependent mechanism. We might have not seen 
a major increase because we were close to the saturation levels of the flow citometry, since both 
values were above 90%. Therefore, in future studies a scale-down of the amount of exosomes 
used to incubate with cells could result in greater exosomes uptake variations. Nonetheless, by 
analyzing the fluorescence intensity from the tumor cell line we observed that cells that 
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internalized GE11+ exosomes had a higher fluorescence intensity median comparing to the 
control condition. This could indicate that not only the percentage of cells that internalized the 
GE11+ exosomes was higher but there were more exosomes per cell, thus enforcing the uptake 
differences results and suggesting a supplementary uptake, EGFR-dependent. Regarding the 
uptake levels of the engineered exosomes by the normal renal cell line there were no significant 
differences and the overall uptake levels went around 20%. These data is in accordance with the 
total EGFR protein levels that were very low in normal renal cells, comparing to tumor renal 
cells. Hence, in the normal cells no significant increase in the uptake of GE11+ exosomes 
comparing to the control was expected. Additionally, there were no statistical significant 
differences between the fluorescence intensity median of HK-2 cells that had internalized GE11+ 
exosomes comparing with the control, which correlated with the overall percentage levels of 
internalization. Moreover, these data suggests that the non-EGFR dependent exosomes uptake 
levels vary between normal and tumor renal cell lines. Regarding the tumor cell line, there was 
approximately a 92% of exosomes uptake that was not EGFR-dependent whereas, for the 
normal renal cell line this value dropped to around 20%. The intrinsic capacity of each cell type 
to internalize exosomes might be different. Recent studies performed by Czernek and colleagues 
showed that the differentiation status of myeloid cells influences the efficiency of exosomes 
uptake since macrophages and mature dendritic cells presented higher exosomes uptake 
comparing to monocytes or immature dendritic cells [137]. Another study conducted by Hazan-
Halevy demonstrated that Mantle cell lymphoma (MCL)-derived exosomes were preferentially 
taken up by MCL cells, when co-cultured with other cell types. However, the specificity of 
exosomes uptake by different target cells remains largely unknown and further studies are 
needed in order to elucidate the underlying mechanisms of these processes. Finally, when 
comparing GE11+ exosomes uptake levels between normal and tumor renal cell lines a 
significant difference was observed. Approximately, 22% of the normal renal cells internalized 
the engineered exosomes, while in the case of the tumor cells the percentage rose to 97%. 
Therefore, according to our data, the use of GE11+ exosomes as a new delivery system in ccRCC 
is very promising.  
Ultimately, engineered extracellular vesicles can be loaded with RNAi-based drugs, for instance 
miRNA mimics or antagonists, and allow a more specific delivery of their content.  It has been 
demonstrated that miRNAs are aberrantly expressed in cancer and that regulate different 
signaling pathways associated with tumor progression [65]. Increasing evidence supports the 
involvement of miRNAs in the regulation of VHL/HIF axis that ultimately affects EGFR-related 
pathways [138]. For instance, miRNA-92 is overexpressed in chronic lymphocytic leukemia B 
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cells and targets VHL mRNA, downregulating its protein levels and promoting HIF/VEGF axis 
activation [139]. Moreover, this miRNA correlated negatively with both VHL mRNA and pVHL 
levels in ccRCC tumor samples [140]. These studies demonstrate the potential role of certain 
miRNAs in central pathways regulation such as the VHL/HIF one. Regarding this axis 
dysregulation it is known that HIF can be directly regulated by p53 through MDM2-mediated 
ubiquitination and proteasome degradation [70]. Furthermore, Wulfken and colleagues 
demonstrated that miRNA-1233 could target p53, based on a bioinformatics approach [72]. 
Thus, we hypothesized that miRNA-1233 could regulate p53 and consequently HIF responses 
related to hypoxia, making him a promising drug target candidate. Indeed, studies developed in 
our research group demonstrated the upregulation of miRNA-1233 in plasma samples of ccRCC 
patients when compared to healthy individuals [71]. In accordance with these findings, the 
tumor renal cell line used in this study presented higher expression levels of miRNA-1233 when 
compared to the normal renal cell line. Besides, TP53 mRNA expression levels were decreased 
in tumor cells which reflects a negative correlation between these two molecules, enforcing our 
hypothesis. However, when the tumor cell line was transfected with a miRNA-1233 mimic, no 
differences were observed in TP53 mRNA levels. However, this result does not discard the 
possibility of TP53 mRNA being a target of miRNA-1233. It is known that miRNAs can induce 
gene repression mainly through two different ways: 1) at the level of mRNA stability by miRNA-
mediated mRNA decay or by sequestration of target mRNAs in P-bodies (cytoplasmic structures 
in which the mRNA degradation machinery is enriched) or 2) at the level of mRNA translation 
including repression of initiation and/or elongation, ribosome drop-off, and nascent polypeptide 
degradation [141, 142]. One frequent mechanism of miRNAs regulation of gene expression is by 
base pairing imperfectly to the 3’UTR sequences of target mRNAs, inhibiting protein synthesis, 
but maintaining the mRNA levels [143]. Therefore, further studies would be necessary to 
completely clarify miRNA-1233 and p53 interaction in order to elucidate its role in the hypoxia-
state maintenance in ccRCC. For instance, by transfecting the tumor renal cell line with a miRNA-
1233 mimic or inhibitor and evaluating p53 protein levels by western-blot. Nonetheless, miRNA-
1233 dysregulation and its potential oncogenic role in ccRCC makes it a new promising candidate 
for drug targeting. MiRNA-1233 inhibition could be achieved by various synthetic modified 
antisense oligonucleotides such as AMOs, LNA anti-miRNAs, miRNA sponges, and others [118]. 
LNA anti-miRNAs are of special interest due to their ability to knock-down miRNAs expression in 
vivo [144]. Although miRNA-based therapeutics appears very promising, there is a major hurdle 
associated with an effective method of delivery. The presence of serum and cellular nucleases 
make these molecules very unstable and thus, unfeasible to use on their own [145, 146]. 
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Additionally, their small size and negative charge interfere with their ability to cross cell 
membrane [146]. Hence, RNAi-based therapeutics requires a targeted delivery vehicle for 
sufficient tissue specificity and cellular uptake. Amongst all the possibilities exosomes have 
received especial attention due to being natural occurring RNA nanocarriers [81, 82, 118]. The 
combination of RNAi-based drugs with engineered exosomes as a new strategy for ccRCC 
treatment is very promising. Additional studies should be performed in order to validate the 
potential use of GE11+ exosomes as a drug delivery vehicle not only in the ccRCC tumor model 
but also in other EGFR-overexpressing tumors. Regarding the use of engineered exosomes in the 
clinic, the insufficient understanding of exosomes role in normal and pathological conditions 
makes it difficult to predict therapeutic effectiveness and long-term safety [147]. More studies 
are necessary in order to clarify exosomes in vivo trafficking, their biological fate and impact on 
targeted organ [76, 148].  
Overall, GE11+ exosomes can be used and loaded with a miRNA-1233 antagonist and potentially 
affect tumor development, becoming a novel therapeutic approach in ccRCC. This strategy can 
be applied in different disease contexts due to the versatility of engineered exosomes and its 
loading with a wide range of RNAi-based drugs, allowing a potent drug targeted effect.  
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6. Conclusion and Future Perspectives 
 
VHL impairment and consequent HIF accumulation is a crucial event in ccRCC initiation, 
responsible for several pathways dysregulation including EGFR activation through TGFα 
production. In the present study, in vitro experiments demonstrated EGFR overexpression and 
overactivation in a metastatic ccRCC cell line. Additionally, downstream signaling MAPK/ERK was 
overactivated since the tumor renal cell line presented higher levels of ERK2 phosphorylated 
form comparing to the normal renal cell line. EGFR downstream signaling is associated with 
various cell signaling pathways that regulate proliferation and survival. Through EGFR 
dysregulation tumor cells become self-sufficient in growth signals which ultimately leads to 
malignancy progression. Although this study has given very useful insights about EGFR 
importance in ccRCC tumor model, in future studies these experiments should be replicated in 
other ccRCC-derived cell lines that could reflect different ccRCC stages of development, since 
we only had the opportunity to use a metastatic ccRCC cell line. Besides, it would also be very 
interesting to analyze other downstream signaling cascades activation, such as PI3K/AKT and 
STAT3 and evaluate if EGFR inhibition would reflect in a downstream inhibition of those 
pathways. Meaning that those cascades activation would arise primarily from EGFR activation, 
once again demonstrating the central role of EGFR in ccRCC progression. Since this tumor is 
resistant to chemotherapy, radiotherapy and to the targeted therapies today applied in the 
clinic, there is the need to develop new therapeutic strategies that overcome these therapy 
limitations. EGFR dysregulation could be the base of new targeted therapies development. 
Recently, exosomes have emerged as new therapeutic tools, since they can be engineered to 
express certain cell type-specific ligands on their surface, like the GE11 synthetic peptide, an 
EGFR ligand. In the present study, exosomes derived from HEK293T cells were engineered in 
order to express the GE11 peptide on their surface and incubated with either normal or tumor 
renal cell lines in vitro at 4°C or 37°C. After incubation at 4°C there was almost complete 
abrogation of exosomes internalization by both renal cell lines suggesting that cells had to be 
biologically active in order for this process to occur. Regarding cells incubation at 37°C, those 
experiments demonstrated that a higher percentage of metastatic ccRCC cells internalized 
GE11+ exosomes comparing to exosomes derived from HEK293T cells transfected with pDisplay, 
the control condition. Besides, the number of GE11+ exosomes per cell was also higher, 
evidencing those uptake differences. Regarding the normal renal cell line, as expected, those 
differences were not observed since their EGFR expression levels were lower when compared 
to the tumor renal cell line. Overall, there was a significant difference between the GE11+ 
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exosomes uptake by the normal and tumor renal cell lines. However, uptake differences of 
GE11+ exosomes were not exclusively due to different EGFR expression levels between both 
renal cell lines, since there was a significant difference concerning the uptake levels in the 
control condition. Nevertheless, these findings suggest that using GE11+ exosomes as a new 
delivery system in ccRCC is very promising. Future studies should include a wider range of ccRCC-
derived cell lines that reflect different EGFR expression status and also additional normal renal 
cell lines in order to evaluate the reproducibility of this delivery system. Engineered exosomes 
are promising delivery vehicles of RNAi-based drugs due to their high stability in circulation and 
targeted cell type-specificity. Increasing evidence supports the involvement of miRNAs in 
VHL/HIF axis regulation as it was hypothesized for miRNA-1233. Despite initial findings that 
miRNA-1233 was upregulated, whereas TP53 mRNA was downregulated in the tumor renal cell 
line comparing to the normal renal cell line, we were not able to find a direct correlation 
between miRNA-1233 and TP53 mRNA. Therefore, in order to evaluate the potential role of 
miRNA-1233 in HIF/EGFR axis regulation, further studies should focus on p53 protein levels 
assessment through a western-blot, upon tumor cells transfection with a miRNA-1233 mimic or 
inhibitor. Furthermore, if this functional relationship was established, it would also be 
interesting to analyze the influence of miRNA-1233 levels variation in HIF and EGFR expression, 
once again possibly through western-blot analysis. Nonetheless, miRNA-1233 high expression 
levels detected in the metastatic ccRCC cell line, in addition to previous findings in plasma 
samples of ccRCC patients, demonstrate the potential importance of this miRNA in ccRCC 
development. Therefore, future studies should center in its in vitro inhibition and evaluation of 
diverse biological processes such as cell proliferation, death, migration, and invasion, since it 
appears a very promising candidate for drug targeting. Ultimately, future experiments should 
include in vivo validation of this delivery system, by using GE11+ exosomes loaded with a miRNA-
1233 antagonist in a ccRCC mice model. These experiments would reveal the potential use of an 
exosome and RNAi-based therapy in ccRCC treatment. 
 
   
 
41 
 
7. References 
 
1. Wild, B.W.S.a.C.P., World Cancer Report 2014. 2014: Lyon, France : International Agency 
for Research on Cancer. 
2. IARC, Latest world cancer statistics, in Global cancer burden rises to 14.1 million new 
cases in 2012: Marked increase in breast cancers must be addressed. 2013: IARC: Lyon. 
p. 1. 
3. Jemal, A., et al., Global cancer statistics. CA: A Cancer Journal for Clinicians, 2011. 61(2): 
p. 69-90. 
4. Internatiotal Agency for Cancer Research. GLOBOCAN 2012: Estimated Cancer 
Incidence, Mortality and Prevalence in 2012. 2012  [cited 2016 17th July]. 
5. Barrett, J.C., Mechanisms of multistep carcinogenesis and carcinogen risk assessment. 
Environmental Health Perspectives, 1993. 100: p. 9-20. 
6. Strahm, B. and M. Capra, Insights into the molecular basis of cancer development. 
Current Paediatrics, 2005. 15(4): p. 333-338. 
7. Abbas, K., Mitchell, F., Robbins Basic Pathology. 9th ed. 2013: Saunders Elsevier. 
8. Brennan, P., Gene-environment interaction and aetiology of cancer: what does it mean 
and how can we measure it? Carcinogenesis, 2002. 23(3): p. 381-387. 
9. Riley, L.B. and D.C. Desai, The Molecular Basis of Cancer and the Development of 
Targeted Therapy. Surgical Clinics of North America, 2009. 89(1): p. 1-15. 
10. Hanahan, D., Weinberg, R.A., The Hallmarks of Cancer. Cell, 2000. 100: p. 57-70. 
11. Hanahan, D., Weinberg, R.A.,, Hallmarks of Cancer: The Next Generation. Cell, 2011. 144: 
p. 646-674. 
12. Merlo, L.M.F., et al., Cancer as an evolutionary and ecological process. Nat Rev Cancer, 
2006. 6(12): p. 924-935. 
13. Barcellos-Hoff, M.H., D. Lyden, and T.C. Wang, The evolution of the cancer niche during 
multistage carcinogenesis. Nat Rev Cancer, 2013. 13(7): p. 511-518. 
14. Upreti, M., A. Jyoti, and P. Sethi, Tumor microenvironment and nanotherapeutics. 
Translational Cancer Research; Vol 2, No 4 (August 2013): Transl Cancer Res. 2013; 2(4): 
p. 309–319. 
15. Frediani, J.N. and M. Fabbri, Essential role of miRNAs in orchestrating the biology of the 
tumor microenvironment. Molecular Cancer, 2016. 15: p. 42. 
16. Siegel, R., D. Naishadham, and A. Jemal, Cancer statistics, 2013. CA: A Cancer Journal for 
Clinicians, 2013. 63(1): p. 11-30. 
 
42 
 
17. Basso, M., A. Cassano, and C. Barone, A survey of therapy for advanced renal cell 
carcinoma. Urologic Oncology: Seminars and Original Investigations. 28(2): p. 121-133. 
18. Gupta, K., et al., Epidemiologic and socioeconomic burden of metastatic renal cell 
carcinoma (mRCC): a literature review. Cancer Treat Rev, 2008. 34(3): p. 193-205. 
19. Znaor, A., et al., International variations and trends in renal cell carcinoma incidence and 
mortality. Eur Urol, 2015. 67(3): p. 519-30. 
20. Ljungberg, B., et al., The Epidemiology of Renal Cell Carcinoma. European Urology, 2011. 
60(4): p. 615-621. 
21. Ljungberg, B., et al., EAU Guidelines on Renal Cell Carcinoma. 2015. 67(5): p 913-24. 
22. Weikert, S. and B. Ljungberg, Contemporary epidemiology of renal cell carcinoma: 
perspectives of primary prevention. World J Urol, 2010. 28(3): p. 247-52. 
23. Chow, W.H., L.M. Dong, and S.S. Devesa, Epidemiology and risk factors for kidney cancer. 
Nat Rev Urol, 2010. 7(5): p. 245-57. 
24. Lindblad, P., Epidemiology of renal cell carcinoma. Scand J Surg, 2004. 93(2): p. 88-96. 
25. Patard, J.J., et al., ICUD-EAU International Consultation on Kidney Cancer 2010: 
treatment of metastatic disease. Eur Urol, 2011. 60(4): p. 684-90. 
26. Bex, A., et al., Integrating surgery with targeted therapies for renal cell carcinoma: 
current evidence and ongoing trials. Eur Urol, 2010. 58(6): p. 819-28. 
27. Chin, A.I., et al., Surveillance Strategies for Renal Cell Carcinoma Patients Following 
Nephrectomy. Reviews in Urology, 2006. 8(1): p. 1-7. 
28. Motzer, R.J., et al., Renal cell carcinoma. Curr Probl Cancer, 1997. 21(4): p. 185-232. 
29. Cohen, H.T. and F.J. McGovern, Renal-cell carcinoma. N Engl J Med, 2005. 353(23): p. 
2477-90. 
30. Yang, J.C., et al., Randomized study of high-dose and low-dose interleukin-2 in patients 
with metastatic renal cancer. J Clin Oncol, 2003. 21(16): p. 3127-32. 
31. Coppin, C., et al., Immunotherapy for advanced renal cell cancer. Cochrane Database 
Syst Rev, 2005(1): p. CD001425. 
32. Abe, H. and T. Kamai, Recent advances in the treatment of metastatic renal cell 
carcinoma. Int J Urol, 2013. 20(10): p. 944-55. 
33. Rini, B.I. and K. Flaherty, Clinical effect and future considerations for molecularly-
targeted therapy in renal cell carcinoma. Urol Oncol, 2008. 26(5): p. 543-9. 
34. Ravaud, A. and M. Gross-Goupil, Overcoming resistance to tyrosine kinase inhibitors in 
renal cell carcinoma. Cancer Treat Rev, 2012. 38(8): p. 996-1003. 
 
43 
 
35. Adem, B.F., et al., miRNAs: mediators of ErbB family targeted therapy resistance. 
Pharmacogenomics, 2016. 17(10): p. 1175-1187. 
36. Ana Luísa Teixeira, F.D., Rui Medeiros, Carcinoma Renal em Tumores Malignos – Tracto 
Génito-Urinário. 1ª ed. Vol. 2. 2016. 
37. Srigley, J.R., et al., The International Society of Urological Pathology (ISUP) Vancouver 
Classification of Renal Neoplasia. Am J Surg Pathol, 2013. 37(10): p. 1469-89. 
38. Delahunt, B. and J.N. Eble, History of the Development of the Classification of Renal Cell 
Neoplasia. Clinics in Laboratory Medicine, 2005. 25(2): p. 231-246. 
39. Smaldone, M.C. and J.K. Maranchie, Clinical implications of hypoxia inducible factor in 
renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations. 27(3): p. 
238-245. 
40. Mulders, P. and Z. Kirkali, Renal Cell Carcinoma: A Changing Paradigm With a Need for 
Consensus. European Urology, 2011. 60(4): p. 613-614. 
41. Robinson, C.M. and M. Ohh, The multifaceted von Hippel-Lindau tumour suppressor 
protein. FEBS Lett, 2014. 588(16): p 2704-11. 
42. Brugarolas, J., Molecular Genetics of Clear-Cell Renal Cell Carcinoma. Journal of Clinical 
Oncology, 2014. 32(18): p. 1968-1976. 
43. Kaelin, W.G., Jr., The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin 
Cancer Res, 2004. 10(18 Pt 2): p. 6290s-5s. 
44. Pugh, C.W. and P.J. Ratcliffe, The von Hippel-Lindau tumor suppressor, hypoxia-inducible 
factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin Cancer Biol, 2003. 13(1): 
p. 83-9. 
45. Loughlin, K.R., Hypoxia inducible factor (HIF): its central role in renal cell cancer targeted 
therapy. Urol Oncol, 2009. 27(3): p. 236-7. 
46. Furniss, D., et al., Prognostic factors for renal cell carcinoma. Cancer Treat Rev, 2008. 
34(5): p. 407-26. 
47. Wenger, R.H., D.P. Stiehl, and G. Camenisch, Integration of oxygen signaling at the 
consensus HRE. Sci STKE, 2005. 2005(306): p. re12. 
48. Smith, K., et al., Silencing of epidermal growth factor receptor suppresses hypoxia-
inducible factor-2-driven VHL-/- renal cancer. Cancer Res, 2005. 65(12): p. 5221-30. 
49. Schechter, A.L., et al., The neu oncogene: an erb-B-related gene encoding a 185,000-Mr 
tumour antigen. Nature, 1984. 312(5994): p. 513-516. 
50. Yarden, Y. and M.X. Sliwkowski, Untangling the ErbB signalling network. Nat Rev Mol 
Cell Biol, 2001. 2(2): p. 127-37. 
 
44 
 
51. Olayioye, M.A., et al., ErbB-1 and ErbB-2 Acquire Distinct Signaling Properties Dependent 
upon Their Dimerization Partner. Molecular and Cellular Biology, 1998. 18(9): p. 5042-
5051. 
52. Yarden, Y. and G. Pines, The ERBB network: at last, cancer therapy meets systems 
biology. Nat Rev Cancer, 2012. 12(8): p. 553-563. 
53. Grandis, J.R. and J.C. Sok, Signaling through the epidermal growth factor receptor during 
the development of malignancy. Pharmacol Ther, 2004. 102(1): p. 37-46. 
54. Roskoski Jr, R., The ErbB/HER family of protein-tyrosine kinases and cancer. 
Pharmacological Research, 2014. 79(0): p. 34-74. 
55. Ravaud, A., et al., Epithelial growth factor receptor (EGFR) pathway and renal cell 
carcinoma. Targeted Oncology, 2007. 2(2): p. 99-105. 
56. Wang, Y., et al., Regulation of endocytosis via the oxygen-sensing pathway. Nat Med, 
2009. 15(3): p. 319-324. 
57. Zhou, L. and H. Yang, The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-
independent poly-ubiquitylation and degradation of the activated EGFR. PLoS One, 
2011. 6(9): p. e23936. 
58. Dias, F., et al., Renal cell carcinoma development and miRNAs: a possible link to the EGFR 
pathway. Pharmacogenomics, 2013. 14(14): p. 1793-1803. 
59. Chow, T.-f.F., et al., Differential expression profiling of microRNAs and their potential 
involvement in renal cell carcinoma pathogenesis. Clinical Biochemistry, 2010. 43(1–2): 
p. 150-158. 
60. Shi, X.-B., C.G. Tepper, and R.W. deVere White, Cancerous miRNAs and their regulation. 
Cell Cycle, 2008. 7(11): p. 1529-1538. 
61. Calin, G.A. and C.M. Croce, MicroRNA signatures in human cancers. Nat Rev Cancer, 
2006. 6(11): p. 857-866. 
62. Cullen, B.R., Transcription and Processing of Human microRNA Precursors. Molecular 
Cell. 16(6): p. 861-865. 
63. Engels, B.M. and G. Hutvagner, Principles and effects of microRNA-mediated post-
transcriptional gene regulation. Oncogene, 0000. 25(46): p. 6163-6169. 
64. Ambros, V., The functions of animal microRNAs. Nature, 2004. 431(7006): p. 350-355. 
65. Zhang, B., et al., microRNAs as oncogenes and tumor suppressors. Developmental 
Biology, 2007. 302(1): p. 1-12. 
 
45 
 
66. Cho, W.C.S., MicroRNAs: Potential biomarkers for cancer diagnosis, prognosis and 
targets for therapy. The International Journal of Biochemistry & Cell Biology, 2010. 
42(8): p. 1273-1281. 
67. Huang, X., et al., Hypoxia inducible mir-210 regulates normoxic gene expression involved 
in tumor initiation. Molecular cell, 2009. 35(6): p. 856-867. 
68. Chow, T.-f.F., et al., The miR-17-92 Cluster is Over Expressed in and Has an Oncogenic 
Effect on Renal Cell Carcinoma. The Journal of Urology. 183(2): p. 743-751. 
69. Yi, Z., et al., Differential expression of miRNA patterns in renal cell carcinoma and 
nontumorous tissues. Journal of Cancer Research and Clinical Oncology, 2010. 136(6): p. 
855-862. 
70. Ravi, R., et al., Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-
inducible factor 1α. Genes & Development, 2000. 14(1): p. 34-44. 
71. Dias, F., Circulating microRNAS and Renal Cell Carcinoma, in Oncobiology. 2014, Instituto 
de Ciências Biomédicas Abel Salazar da Universidade do Porto. 
72. Wulfken, L.M., et al., MicroRNAs in Renal Cell Carcinoma: Diagnostic Implications of 
Serum miR-1233 Levels. PLoS ONE, 2011. 6(9): p. e25787. 
73. Rivlin, N., et al., Mutations in the p53 Tumor Suppressor Gene: Important Milestones at 
the Various Steps of Tumorigenesis. Genes & Cancer, 2011. 2(4): p. 466-474. 
74. Dameron, K.M., et al., Control of angiogenesis in fibroblasts by p53 regulation of 
thrombospondin-1. Science, 1994. 265(5178): p. 1582-1584. 
75. Mukhopadhyay, D., L. Tsiokas, and V.P. Sukhatme, Wild-Type p53 and v-Src Exert 
Opposing Influences on Human Vascular Endothelial Growth Factor Gene Expression. 
Cancer Research, 1995. 55(24): p. 6161-6165. 
76. Ren, J., et al., From structures to functions: insights into exosomes as promising drug 
delivery vehicles. Biomaterials Science, 2016. 4(6): p. 910-921. 
77. Colombo, M., G. Raposo, and C. Théry, Biogenesis, Secretion, and Intercellular 
Interactions of Exosomes and Other Extracellular Vesicles. Annual Review of Cell and 
Developmental Biology, 2014. 30(1): p. 255-289. 
78. Mathivanan, S., H. Ji, and R.J. Simpson, Exosomes: Extracellular organelles important in 
intercellular communication. Journal of Proteomics, 2010. 73(10): p. 1907-1920. 
79. Lakkaraju, A. and E. Rodriguez-Boulan, Itinerant exosomes: emerging roles in cell and 
tissue polarity. Trends in cell biology, 2008. 18(5): p. 199-209. 
80. Simpson, R.J., S.S. Jensen, and J.W.E. Lim, Proteomic profiling of exosomes: Current 
perspectives. PROTEOMICS, 2008. 8(19): p. 4083-4099. 
 
46 
 
81. Sato-Kuwabara, Y., et al., The fusion of two worlds: Non-coding RNAs and extracellular 
vesicles - diagnostic and therapeutic implications (Review). International Journal of 
Oncology, 2015. 46(1): p. 17-27. 
82. Valadi, H., et al., Exosome-mediated transfer of mRNAs and microRNAs is a novel 
mechanism of genetic exchange between cells. Nat Cell Biol, 2007. 9(6): p. 654-659. 
83. De Toro, J., et al., Emerging Roles of Exosomes in Normal and Pathological Conditions: 
New Insights for Diagnosis and Therapeutic Applications. Frontiers in Immunology, 
2015. 6: p. 203. 
84. Wolfers, J., et al., Tumor-derived exosomes are a source of shared tumor rejection 
antigens for CTL cross-priming. Nat Med, 2001. 7(3): p. 297-303. 
85. Admyre, C., et al., B cell&#x2013;derived exosomes can present allergen peptides and 
activate allergen-specific T cells to proliferate and produce T<sub>H</sub>2-like 
cytokines. Journal of Allergy and Clinical Immunology. 120(6): p. 1418-1424. 
86. Marcilla, A., et al., Extracellular Vesicles from Parasitic Helminths Contain Specific 
Excretory/Secretory Proteins and Are Internalized in Intestinal Host Cells. PLoS ONE, 
2012. 7(9): p. e45974. 
87. Rodrigues, M.L., et al., The impact of proteomics on the understanding of functions and 
biogenesis of fungal extracellular vesicles. Journal of proteomics, 2014. 97: p. 177-186. 
88. Lachenal, G., et al., Release of exosomes from differentiated neurons and its regulation 
by synaptic glutamatergic activity. Molecular and Cellular Neuroscience, 2011. 46(2): p. 
409-418. 
89. Ghidoni, R., L. Benussi, and G. Binetti, Exosomes: The Trojan horses of 
neurodegeneration. Medical Hypotheses. 70(6): p. 1226-1227. 
90. Bellingham, S.A., et al., Exosomes: Vehicles for the Transfer of Toxic Proteins Associated 
with Neurodegenerative Diseases? Frontiers in Physiology, 2012. 3: p. 124. 
91. Emmanouilidou, E., et al., Cell-Produced α-Synuclein Is Secreted in a Calcium-Dependent 
Manner by Exosomes and Impacts Neuronal Survival. The Journal of Neuroscience, 2010. 
30(20): p. 6838-6851. 
92. Melo, S.A., et al., Glypican1 identifies cancer exosomes and facilitates early detection of 
cancer. Nature, 2015. 523(7559): p. 177-182. 
93. Salido-Guadarrama, I., et al., MicroRNAs transported by exosomes in body fluids as 
mediators of intercellular communication in cancer. OncoTargets and therapy, 2014. 7: 
p. 1327-1338. 
 
47 
 
94. Rana, S., K. Malinowska, and M. Zöller, Exosomal Tumor MicroRNA Modulates 
Premetastatic Organ Cells. Neoplasia (New York, N.Y.), 2013. 15(3): p. 281-295. 
95. Xiang, X., et al., Induction of myeloid-derived suppressor cells by tumor exosomes. 
International journal of cancer. Journal international du cancer, 2009. 124(11): p. 2621-
2633. 
96. Yu, S., et al., Tumor Exosomes Inhibit Differentiation of Bone Marrow Dendritic Cells. The 
Journal of Immunology, 2007. 178(11): p. 6867-6875. 
97. Valenti, R., et al., Human tumor-released microvesicles promote the differentiation of 
myeloid cells with transforming growth factor-beta-mediated suppressive activity on T 
lymphocytes. Cancer Res, 2006. 66(18): p. 9290-8. 
98. Wieckowski, E.U., et al., Tumor-Derived Microvesicles Promote Regulatory T Cell 
Expansion and Induce Apoptosis in Tumor-Reactive Activated CD8(+) T Lymphocytes(). 
Journal of immunology (Baltimore, Md. : 1950), 2009. 183(6): p. 3720-3730. 
99. Skog, J., et al., Glioblastoma microvesicles transport RNA and protein that promote 
tumor growth and provide diagnostic biomarkers. Nature cell biology, 2008. 10(12): p. 
1470-1476. 
100. Al-Nedawi, K., et al., Endothelial expression of autocrine VEGF upon the uptake of tumor-
derived microvesicles containing oncogenic EGFR. Proceedings of the National Academy 
of Sciences of the United States of America, 2009. 106(10): p. 3794-3799. 
101. Sidhu, S.S., et al., The microvesicle as a vehicle for EMMPRIN in tumor-stromal 
interactions. Oncogene, 0000. 23(4): p. 956-963. 
102. E S. Zacharias, et al., Therapeutic uses of exosomes. Exosomes Microvesicles, 2013. 1(5)  
103. Kim, S.H., et al., Effective Treatment of Inflammatory Disease Models with Exosomes 
Derived from Dendritic Cells Genetically Modified to Express IL-4. The Journal of 
Immunology, 2007. 179(4): p. 2242-2249. 
104. Zitvogel, L., et al., Eradication of established murine tumors using a novel cell-free 
vaccine: dendritic cell derived exosomes. Nat Med, 1998. 4(5): p. 594-600. 
105. Escudier, B., et al., Vaccination of metastatic melanoma patients with autologous 
dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. Journal of 
Translational Medicine, 2005. 3: p. 10-10. 
106. Morse, M.A., et al., A phase I study of dexosome immunotherapy in patients with 
advanced non-small cell lung cancer. Journal of Translational Medicine, 2005. 3: p. 9-9. 
 
48 
 
107. Gustave Roussy, Cancer Campus, Grand Paris. Trial of a Vaccination With Tumor 
Antigen-loaded Dendritic Cell-derived Exosomes (CSET 1437). NLM identifier: 
NCT01159288.Available from https://clinicaltrials.gov/ct2/show/results/NCT01159288. 
108. Dai, S., et al., Phase I Clinical Trial of Autologous Ascites-derived Exosomes Combined 
With GM-CSF for Colorectal Cancer. Mol Ther, 2008. 16(4): p. 782-790. 
109. Lai, R.C., et al., Exosomes for drug delivery - a novel application for the mesenchymal 
stem cell. Biotechnol Adv, 2013. 31(5): p. 543-51. 
110. Raemdonck, K., et al., Merging the best of both worlds: hybrid lipid-enveloped matrix 
nanocomposites in drug delivery. Chemical Society Reviews, 2014. 43(1): p. 444-472. 
111. Li, C., et al., Biocompatible and biodegradable nanoparticles for enhancement of anti-
cancer activities of phytochemicals. Chinese Journal of Natural Medicines, 2015. 13(9): 
p. 641-652. 
112. Silva, M. and S.A. Melo, Non-coding RNAs in Exosomes: New Players in Cancer Biology. 
Current Genomics, 2015. 16(5): p. 295-303. 
113. James Graham Brown Cancer Center; University of Louisville. Study investigating the 
ability of plant exosomes to deliver curcumin to normal and colon cancer tissue. NLM 
identifier: NCT01294072. Available from https://clinicaltrials.gov/show/NCT01294072. 
114. Johnson, S.M., et al., Curcumin Inhibits Proliferation of Colorectal Carcinoma by 
Modulating Akt/mTOR Signaling. Anticancer research, 2009. 29(8): p. 3185-3190. 
115. El Andaloussi, S., et al., Extracellular vesicles: biology and emerging therapeutic 
opportunities. Nat Rev Drug Discov, 2013. 12(5): p. 347-357. 
116. Malone, C.D. and G.J. Hannon, Small RNAs as Guardians of the Genome. Cell, 2009. 
136(4): p. 656-668. 
117. Alvarez-Erviti, L., et al., Delivery of siRNA to the mouse brain by systemic injection of 
targeted exosomes. Nat Biotech, 2011. 29(4): p. 341-345. 
118. Shah, M.Y. and G.A. Calin, MicroRNAs as therapeutic targets in human cancers. Wiley 
interdisciplinary reviews. RNA, 2014. 5(4): p. 537-548. 
119. Melo, S.A. and R. Kalluri, Molecular Pathways: MicroRNAs as Cancer Therapeutics. 
Clinical Cancer Research, 2012. 18(16): p. 4234. 
120. Garzon, R., G. Marcucci, and C.M. Croce, Targeting microRNAs in cancer: rationale, 
strategies and challenges. Nat Rev Drug Discov, 2010. 9(10): p. 775-789. 
121. Ohno, S.-i., et al., Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor 
MicroRNA to Breast Cancer Cells. Molecular Therapy, 2013. 21(1): p. 185-191. 
 
49 
 
122. Li, Z., et al., Identification and characterization of a novel peptide ligand of epidermal 
growth factor receptor for targeted delivery of therapeutics. Faseb j, 2005. 19(14): p. 
1978-85. 
123. Sempere, L.F., et al., Altered MicroRNA Expression Confined to Specific Epithelial Cell 
Subpopulations in Breast Cancer. Cancer Research, 2007. 67(24): p. 11612-11620. 
124. Minner, S., et al., Epidermal growth factor receptor protein expression and genomic 
alterations in renal cell carcinoma. Cancer, 2012. 118(5): p. 1268-1275. 
125. Théry, C., et al., Isolation and Characterization of Exosomes from Cell Culture 
Supernatants and Biological Fluids, in Current Protocols in Cell Biology. 2001, John Wiley 
& Sons, Inc. Chapter 3. Unit 3.22. 
126. de Paulsen, N., et al., Role of transforming growth factor-α in von Hippel– Lindau 
(VHL)(−/−) clear cell renal carcinoma cell proliferation: A possible mechanism coupling 
VHL tumor suppressor inactivation and tumorigenesis. Proceedings of the National 
Academy of Sciences of the United States of America, 2001. 98(4): p. 1387-1392. 
127. Franovic, A., et al., Translational up-regulation of the EGFR by tumor hypoxia provides a 
nonmutational explanation for its overexpression in human cancer. Proceedings of the 
National Academy of Sciences of the United States of America, 2007. 104(32): p. 13092-
13097. 
128. Oda, K., et al., A comprehensive pathway map of epidermal growth factor receptor 
signaling. Molecular Systems Biology, 2005. 1: p. 2005.0010-2005.0010. 
129. Roberts, P.J. and C.J. Der, Targeting the Raf-MEK-ERK mitogen-activated protein kinase 
cascade for the treatment of cancer. Oncogene, 0000. 26(22): p. 3291-3310. 
130. Richard, D.E., et al., p42/p44 Mitogen-activated Protein Kinases Phosphorylate Hypoxia-
inducible Factor 1α (HIF-1α) and Enhance the Transcriptional Activity of HIF-1. Journal of 
Biological Chemistry, 1999. 274(46): p. 32631-32637. 
131. Sang, N., et al., MAPK Signaling Up-regulates the Activity of Hypoxia-inducible Factors 
by Its Effects on p300. Journal of Biological Chemistry, 2003. 278(16): p. 14013-14019. 
132. Merseburger, A.S., et al., Membranous Expression and Prognostic Implications of 
Epidermal Growth Factor Receptor Protein in Human Renal Cell Cancer. Anticancer 
Research, 2005. 25(3B): p. 1901-1907. 
133. Đorđević, G., et al., EGFR protein overexpression correlates with chromosome 7 
polysomy and poor prognostic parameters in clear cell renal cell carcinoma. Journal of 
Biomedical Science, 2012. 19(1): p. 40-40. 
 
50 
 
134. Parolini, I., et al., Microenvironmental pH Is a Key Factor for Exosome Traffic in Tumor 
Cells. The Journal of Biological Chemistry, 2009. 284(49): p. 34211-34222. 
135. Franzen, C.A., et al., Characterization of Uptake and Internalization of Exosomes by 
Bladder Cancer Cells. BioMed Research International, 2014. 2014: p. 11. 
136. Tian, T., et al., Visualizing of the cellular uptake and intracellular trafficking of exosomes 
by live-cell microscopy. Journal of Cellular Biochemistry, 2010. 111(2): p. 488-496. 
137. Czernek, L., A. Chworos, and M. Duechler, The Uptake of Extracellular Vesicles is Affected 
by the Differentiation Status of Myeloid Cells. Scandinavian Journal of Immunology, 
2015. 82(6): p. 506-514. 
138. Li, M., et al., MicroRNAs in renal cell carcinoma: A systematic review of clinical 
implications (Review). Oncology Reports, 2015. 33(4): p. 1571-1578. 
139. Ghosh, A.K., et al., Aberrant regulation of pVHL levels by microRNA promotes the 
HIF/VEGF axis in CLL B cells. Blood, 2009. 113(22): p. 5568-5574. 
140. Valera, V.A., et al., Regulatory Effects of microRNA-92 (miR-92) on VHL Gene Expression 
and the Hypoxic Activation of miR-210 in Clear Cell Renal Cell Carcinoma. Journal of 
Cancer, 2011. 2: p. 515-526. 
141. Morozova, N., et al., Kinetic signatures of microRNA modes of action. RNA, 2012. 18(9): 
p. 1635-1655. 
142. He, L. and G.J. Hannon, MicroRNAs: small RNAs with a big role in gene regulation. Nat 
Rev Genet, 2004. 5(7): p. 522-531. 
143. Filipowicz, W., et al., Post-transcriptional gene silencing by siRNAs and miRNAs. Current 
Opinion in Structural Biology, 2005. 15(3): p. 331-341. 
144. Elmén, J., et al., Antagonism of microRNA-122 in mice by systemically administered LNA-
antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. 
Nucleic Acids Research, 2008. 36(4): p. 1153-1162. 
145. Zhao, X., et al., Controlled delivery of antisense oligonucleotides: a brief review of current 
strategies. Expert Opinion on Drug Delivery, 2009. 6(7): p. 673-686. 
146. Aagaard, L. and J.J. Rossi, RNAi Therapeutics: Principles, Prospects and Challenges. 
Advanced drug delivery reviews, 2007. 59(2-3): p. 75-86. 
147. Ha, D., N. Yang, and V. Nadithe, Exosomes as therapeutic drug carriers and delivery 
vehicles across biological membranes: current perspectives and future challenges. Acta 
Pharmaceutica Sinica B, 2016. 6(4): p. 287-296. 
148. Taylor, D.D. and S. Shah, Methods of isolating extracellular vesicles impact down-stream 
analyses of their cargoes. Methods, 2015. 87: p. 3-10. 
 
51 
 
8. Attachments 
 
 
 
Pharmacogenomics (Epub ahead of print) ISSN 1462-2416
part of
PharmacogenomicsReview
10.2217/pgs-2016-0038 © 2016 Future Medicine Ltd
Pharmacogenomics
Review 2016/05/30
17
10
2016
The ErbB/HER tyrosine kinase receptors family plays a key regulatory role in different 
cellular processes by activating several signaling pathways. In different tumor types, 
mutations or overexpression of the ErbB family members are a common feature, 
which led to the development of targeted therapies against this receptors. Although 
with this kind of treatment we are heading to a more personalized medicine, the 
development of acquired resistance is still an issue, therefore, several studies focused 
on discovering the mechanisms behind it. More recently, miRNAs have been described 
as important mediators of acquired resistance, specifically, acquired resistance to ErbB 
family targeted therapies. Ultimately, miRNA-based therapeutics using exosomes as a 
drug delivery model can revolutionize today’s approach of cancer treatment. 
First draft submitted: 3 March 2016; Accepted for publication 5 April 2016; Published 
online: 30 June 2016
Keywords: acquired resistance • ErbB family • exosomes • miRNAs • targeted therapies
Background
miRNAs
miRNAs are a class of noncoding RNAs 
(19–25 nucleotides in length) that control 
gene expression by either degrading or block-
ing translation of mRNAs, a process that 
depends on the miRNA and the respective 
mRNA target degree of complementar-
ity [1]. miRNA biogenesis is a multiphase 
process which initiates at the nucleus with 
the transcription of a primary RNA, the 
pri-miRNA, by RNA polymerase II [2]. Fol-
lowing transcription, pri-miRNA is pro-
cessed by Drosha, a RNase III endonuclease, 
alongside with cofactor DGCR8, creating 
a pre-miRNA [3]. This precursor ultimately 
is exported to the cytoplasm by Exportin 5 
where is processed by another RNase, Dicer, 
leading to the production of a mature 22 base 
pairs miRNA duplex [2]. The mature miRNA 
enters the RNA-induced silencing complex 
(RISC), whose main components are TRBP, 
AGO1–4, GEMIN3 and GEMIN4 becom-
ing, ultimately, a functional miRNA [4]. 
This complex binds to the target mRNA at 
3′UTR region by complementarity leading 
to gene silencing [5].
A miRNA is not specific for a certain 
mRNA, it can regulate up to 100 different 
mRNAs and is also described that more than 
10,000 mRNAs seem to be regulated by 
miRNAs [6]. Thus, changes in the miRNA 
processing and expression patterns could be 
associated with different pathologies, includ-
ing cancer, suggesting that miRNAs are 
involved in many cellular function disorders, 
which includes carcinogenesis [7].
After the discovery of miRNA-15a and 
miRNA-16-1 as the first miRNAs with 
tumor suppressor functions in chronic lym-
phocytic leukemia in 2002, many miRNAs 
have been described as mediators of cancer-
related signaling pathways, regulating pro-
liferation, apoptosis, angiogenesis and even 
epithelial–mesenchymal transition (EMT), a 
key step for the metastatic process [8,9]. Since 
miRNAs are associated with different bio-
logical processes, they have been described 
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to act as oncogenes, tumor suppressors or even modu-
lators of cancer stem cells and metastasis formation. 
Oncomi RNAs are, usually, overexpressed in cancer 
since they are known to downregulate tumor suppres-
sor genes and tumor suppressor miRNAs are respon-
sible for downregulating oncogenes, so are mostly 
underexpressed in malign neoplasms [10,11]. However, 
this dichotomous approach may have its limitations. 
For example, miRNA-17 is associated, in B-cell lym-
phoma, with faster tumor development, while it can 
suppress cancer growth by downregulating AIB1 
expression in breast cancer [12,13]. Therefore, we have 
to take in consideration the fact that miRNAs may act 
in a tissue-specific manner such that a single miRNA 
can be either an oncomiRNA or a tumor suppressor 
miRNA.
Regarding the miRNAs role in cellular processes 
such as proliferation, apoptosis or angiogenesis, it is 
important to take into account the effect that changes 
in miRNA levels may have in treatment response, 
since targeted therapies are used for specific pro-
teins and  signal pathways related with this biological 
 processes [8,9].
Cancer treatment
Chemotherapy, along with surgery and radiotherapy, 
has been a crucial approach for cancer treatment. 
These different types of treatment can be used alone 
or in different combinations, and either simultane-
ously or sequentially. However, chemotherapy-/radio-
therapy-induced cell damage occurs preferentially 
but not exclusively in cancer cells, causing many side-
effects [14]. For this reason, nowadays, a big effort is 
being made in order to improve a personalized medi-
cine that focus on the discovery and development 
of molecular targeted drugs that take advantage of 
genetic addictions, dependencies and vulnerabilities of 
cancer cells. This type of methodology would be more 
specific than previous described approaches by mini-
mizing side effects on normal cells [15]. Additionally, 
different high-throughput technologies, still under 
development, like genome sequencing and various 
kinds of microarrays, will allow the knowledge of the 
genetic, epigenetic and proteomic background, from 
each individual and tumor, which ultimately will lead 
to a more personalized treatment [16].
The concept of targeting a pathogenic driver abnor-
mality using a small molecule was first validated in 
1988 by the successful treatment of patients with acute 
promyelocytic leukemia harboring translocations in 
the RARα gene with all-trans retinoic acid [17]. Addi-
tionally, the use of imatinib, a BCR-ABL inhibitor, as a 
chronic myeloid leukemia treatment in 1996, marked 
the era of the design of small therapeutic molecules 
applied in cancer treatment [18]. The 5-year estimated 
overall survival rate for patients with this malignancy, 
characterized by the BCR-ABL translocation, was 
89% when imatinib was used as initial therapy [19].
Even with all this development and improvement 
in cancer therapy, resistance to treatment still exists. 
Therapy failure is often due to development of drug 
resistance that may be inherent in a subpopulation of 
heterogeneous cancer cells or acquired subsequent to 
treatment [20]. A well-characterized resistance mecha-
nism is related with the activity of ABC transporters. 
ABC transporters are transmembrane proteins respon-
sible for the transport of a wide variety of substrates 
across cellular membranes, including hydrophobic 
drugs and antibiotic [21,22]. Overexpression of these 
proteins can be associated with reduced drug uptake, 
increased drug efflux and lead to lower drug efficacy 
and possibly to acquire drug resistance due to low drug 
levels in the cytoplasm [22]. The major members of the 
ABC transporters associated with multidrug resistance 
in cancer cells are ABCB1/MDR1, ABCCs (MRPs) 
and ABCG2 (BCRP/MXR/ABCP) [23]. However, 
several ABC transporters have been identified as trans-
porters of cancer chemotherapeutics agents, acquired 
chemotherapy drug resistance can occur at many lev-
els, modulated either by genetic or epigenetic factors. 
In fact, recent data demonstrate that the activity of 
certain miRNAs might be altered in order to achieve 
resistance to chemotherapy [24]. In the same line of 
thought, miRNAs can be as well linked to acquired 
resistance in molecular targeted therapy in several 
malignancy treatments. Latest evidences support this 
idea as it will be described next.
This review focus in the role of miRNAs as mediators 
of acquired resistance in ErbB family targeted therapies 
since this family plays a key regulatory role in nearly 
every aspect of cell biology. The ErbB/HER family 
contains four tyrosine kinase receptors, the epidermal 
growth factor receptor (EGFR/ErbB/Her1), Her2 (Neu, 
ErbB2), Her3 (ErbB3) and Her4 (ErbB4) [25]. Different 
factors as the identity of the ligand and oligomer com-
position of the receptor determine the specificity and 
potency of intracellular signals [26]. Downstream ErbB 
signaling includes phosphatidylinositol 3-kinase/Akt 
(PKB) pathway, the Ras/Raf/MEK/ERK 1/2 pathway 
and the phospholipase C (PLC-γ) pathway [27]. All of 
these pathways are interconnected and overlapping [26]. 
Overall, they regulate apoptosis, cell cycle progression, 
cytoskeletal rearrangement, differentiation, develop-
ment, immune response, nervous system function and 
transcription [28]. Mutations or increased expression 
of ErbB family members occur in several malignan-
cies [26,29]. For instance, ErbB1 overexpression occurs 
in head and neck, breast, bladder, prostate, kidney, 
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non-small-cell lung cancer (NSCLC) and glioma 
tumors, while mutations leading to a constitutively 
active receptor occur in glioma, lung, ovary and breast 
cancer. Overexpression of ErbB2 is frequent in breast, 
lung, pancreatic, colon, esophagus, endometrium and 
cervix cancer, whereas ErbB3 is overexpressed in oral 
squamous cell cancer [26,30].
Several targeted drugs have been developed against 
these protein kinases, however, cancers submitted to 
targeted therapy eventually become resistant [31,32]. 
miRNAs may be a way not only to unveil resistance 
mechanisms (Table 1) but also, if used as a treatment 
option, to overcome targeted therapy limitations.
miRNAs & targeted therapy resistance
ErbB targeted therapies resistance in cancer
Head & neck cancer
Head and neck squamous cell carcinoma (HNSCC) 
is the sixth most common form of cancer worldwide 
with 650,000 new cases each year [45]. Palliative 
chemo therapy and the EGFR inhibitor, cetuximab, 
constitute the backbone of treatment for patients 
with HNSCC [46]. However, many patients with 
HNSCC tumors do not respond to EGFR-targeting 
 therapies [47].
Hatakeyama and coworkers demonstrated that one 
potential mechanism of acquired resistance to cetux-
imab in HNSCC involves the increased expression of 
HB-EGF that is regulated by miRNA-212. HB-EGF is 
known to bind both EGFR and HER4 and to induce 
EMT, enhance metastasis and modulate  chemot herapy 
resistance [48–50]. miRNA-212 showed a 27-fold 
decrease in 1Cc8 cetuximab-resistant cell line relative 
to SCC1 cetuximab-sensitive cell line. Expression lev-
els of HB-EGF and miRNA-212 were also examined 
in 32 additional HNSCC cell lines and keratinocyte 
cell line, demonstrating the inverse correlation of this 
two parameters. Increased expression of HB-EGF 
regulated by miRNA-212 and activation of receptor 
kinases other than EGFR, like HER3 and MET, and 
subsequent activation of AKT, were observed in 1Cc8 
cell line, and may play an important role in acquired 
resistance to cetuximab [33].
Lung cancer
Lung cancer is the leading cause of cancer related 
death worldwide [51]. Of all lung cancer cases, approxi-
mately 80–85% correspond to NSCLC [52]. One of 
the main issues regarding the therapeutic approach 
using chemotherapy or EGFR-tyrosine kinase inhibi-
tors (TKIs) in NSCLC is the acquired resistance that 
develops short after treatment [35,53]. In fact, the role 
of miRNAs, more specifically miRNA-21, has already 
been reported in NSCLC as a modulator of chemo-
therapy sensitivity [54]. Additionally, Shen et al. stated 
that this same miRNA correlated with PTEN levels 
(one of its most important targets) modulates gefitinib 
resistance in the same tumor model [55]. They ana-
Table 1. Summary of the miRNAs involved in the acquired resistance to ErbB family targeted 
therapies by cancer type.
Cancer Targeted Therapy miRNA involved Ref.
Head and neck cancer Cetuximab ↓ miRNA-212 [33]
Lung cancer Erlotinib ↑ miRNA-200 family [34]
 Gefitinib ↑ miRNA-21 [35]
  ↑ miRNA-30c, ↓ miRNA-103, ↓ miRNA-203, 
↑ miRNA-221 and ↑ miRNA-222
[36]
  ↑ miRNA-214 [37]
  ↑ miRNA-374a and ↓ miRNA-548b [38]
Gastric cancer Trastuzumab ↑ miRNA-21 [39]
Breast cancer Trastuzumab ↑ miRNA-21 [40]
  ↑ miRNA-221 [41]
  ↓ miRNA-375 [42]
 Lapatinib ↓ miRNA-630 [43]
 Neratinib   
 Afatinib   
Coloretal cancer Cetuximab ↓ miRNA-let7b, ↓ miRNA-let7e and 
↑ miRNA-17 
[44]
↑: Upregulation; ↓: Downregulation.
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lyzed the expression of miRNA-21 and PTEN protein 
in tumor tissues from NSCLC patients, comparing 
cancer tumor specimens with adjacent normal tis-
sues. A significantly higher expression of miRNA-21 
and a reduction in PTEN protein levels was found in 
tumor tissues, demonstrating a negative correlation. 
High miRNA-21/low PTEN expression levels indi-
cated a poor TKI clinical response and shorter over-
all survival in NSCLC patients. In order to test the 
effect of high miRNA-21/low PTEN expression on 
modulation of TKI sensitivity, a PC-9 TKI-sensitive 
cell line and a gefitinib-resistant cell line PC-9/GR 
were used. In vitro assays showed that miRNA-21 
was upregulated concomitantly to downregulation of 
PTEN in PC-9/GR cells. Moreover, overexpression of 
miRNA-21 significantly decreased gefitinib sensitiv-
ity by down-regulating PTEN expression and activat-
ing AKT and ERK pathways in PC-9 cells. Whereas, 
miRNA-21 knockdown dramatically restored gefi-
tinib sensitivity of PC-9/GR cells by up-regulation of 
PTEN expression and inactivation of AKT and ERK 
pathways, both in vivo and in vitro [56].
Another study performed by Izumchenko and 
coworkers demonstrated that TGFβ–miRNA200–
MIG6 pathway coordinates the EMT-associated 
kinase switch that induces resistance to EGFR inhibi-
tors [34]. They evaluated pairs of cancer cell lines with 
wild-type EGFR that were either sensitive (epithelial-
like) or resistant (mesenchymal-like) to erlotinib, 
an EGFR TKI. Treatment of erlotinib-sensitive cell 
lines with TGFβ resulted in complete EMT. Cells 
with induced mesenchymal phenotype, had both 
total EGFR and phospho-EGFR reduced and elevated 
expression of MIG6, acquiring a relative resistance 
to erlotinib, associated with a significant increase in 
AKT activity, due to higher levels of phospho IGFR, 
PDGFR, FGFR and FAK kinases [36,57]. Concurrently, 
expression levels of miRNA200 family decreased 
significantly. During TGFβ-mediated EMT, inhibi-
tion of the miRNAs 200 family results in upregu-
lated expression of the MIG6, a negative regulator 
of EGFR. The MIG6-mediated reduction of EGFR 
occurs concomitantly with a TGFβ-induced EMT-
associated kinase switch of tumor cells to an AKT-
activated EGFR-independent state. The expression 
levels MIG6 (mRNA)/miRNA200 ratio were inversely 
correlated with EMT and resistance to erlotinib, in 
both in vitro and in vivo models. Demon strating that 
TGF-β–miRNA200–MIG6 network orchestrates the 
EMT-associated kinase switch that induces resistance 
to EGFR inhibitors [34].
Studies in NSCLC also revealed an involvement of 
MET oncogene in TKIs resistance [37,58]. Garofalo and 
coworkers demonstrated that MET and EGFR-related 
miRNAs had a significant role in gefitinib resistance on 
NSCLC cell lines and in vivo models. NSCLC gefitinib-
resistant cell lines, Calu-1 and A549, did not revealed 
an expected miRNA-30b-c and miRNA-221/-222 
down-regulation and consequent increase in BIM and 
APAF-1 protein levels after treatment. miRNA-30b-c 
and miRNA-221/-222 knockdown increased gefitinib 
sensitivity in resistant and sensitive gefitinib cell lines 
indicating that these miRNAs are important modula-
tors of TKI resistance. Results from the same paper 
also show that MET overexpression controls gefitinib 
resistance through activation of the AKT/ERKs path-
way, mediated at least in part by the miRNA-103 and 
-203 downregulation since an induced expression of 
these miRNAs increases Calu-1 cells gefitinib sensi-
tivity. Additionally, Dicer knockdown reduced gefi-
tinib resistance and also migration and the expression 
of mesenchymal markers. Since miRNA-103 targets 
Dicer, these results may suggest that this miRNA could 
be involved in the EMT process through Dicer down-
regulation. Ultimately, all these results were supported 
by in vivo studies since miRNA-103 and miRNA-203 
overexpression or miRNA-221 and -30c knockdown 
resulted in tumor growth inhibition and increased 
 sensitivity to gefitinib in nude mice after treatment [59].
miRNA-214 has also been described as a gefitinib 
resistance mediator [60]. After exposure to increas-
ing concentrations of gefitinib, studies performed by 
Y-S Wang and coworkers in the resistant clone of a 
lung adenocarcinoma cell line, HCC827/GR, revealed 
an overexpression of miRNA-214. The upregulation 
of this miRNA leads to a PTEN down-regulation, 
which is involved in PI3K–AKT pathway [57]. PTEN 
protein dephosphorylates PI3K, that mediates activa-
tion of AKT, ultimately leading to an inactivation of 
this pathway [38]. So, miRNA-214 mediates gefitinib 
resistance in this model by activating PI3K/AKT path-
way, which has been described to confer resistance to 
EGFR-TKI by overcoming the EGFR blocking in pre-
vious studies [61]. Finally, miRNA-214 knockdown led 
to gefitinib sensitivity in HCC827/GR [60].
Additionally, other studies performed by Wang et al. 
also revealed a gefitinib resistance in NSCLC cell lines 
and in vivo models, but this time mediated by Axl-
altered miRNAs. Findings of the involvement of Axl 
kinase in acquired resistance to TKIs in this tumor 
model were prior to this article but Wang and his fellow 
workers proposed the involvement of the miRNA-374a 
and miRNA-548b in this resistance [62]. Analysis of 
the miRNA expression profile was performed in a gen-
erated gefitinib-resistant cell line, HCC827-Gef, in 
Calu1 cell line, which is resistant to TKI, and in tumor 
samples. Results revealed a relationship between Axl 
overexpression and the overexpression of miRNA-374a 
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and downregulation of miRNA-548b not only in the 
gefitinib-resistant cell lines but also in tumor samples. 
Knockdown of miRNA-374a and upregulation of 
miRNA-548b increased the sensitivity to gefitinib in 
gefitinib-resistant cell lines revealing their importance in 
this mechanism. Finally, results from the same authors 
also showed that miRNA-374a and miRNA-548b not 
only have a role in gefitinib sensitivity and gefitinib-
induced apoptosis but also essential roles in cell cycle 
arrest, EMT, migration and tumorigenesis of gefi-
tinib-resistant lung cancer cells in vitro and in vivo by 
 targeting WNT5A and CCNB1,  respectively [63].
Gastric cancer
Gastric cancer (GC) is the fourth most commonly diag-
nosed cancer and the second most common cause of 
cancer related death worldwide [39]. Results from a recent 
large-scale Phase III study demonstrated that trastu-
zumab combined with standard chemotherapy provided 
a significant survival advantaged compared with chemo-
therapy alone in advanced HER2-positive GC [64]. Even 
though trastuzumab can prolong the survival of patients 
with HER2-positive GC, most of them end up develop-
ing resistance, highlighting the importance in clarifying 
the mechanisms behind this event [65].
Eto and coworkers described that miRNA-21/PTEN 
pathway regulated the sensitivity of HER2-positive 
GC cell lines to trastuzumab through modulation of 
apoptosis. On one hand, they were able to demonstrate 
that overexpression of miRNA-21 not only downregu-
lated PTEN expression but also increased AKT phos-
phorylation, however, not affecting HER2 expres-
sion. On the other hand, suppression of miRNA-21 
increased PTEN expression and downregulated AKT 
phos phorylation, still not affecting HER2 expression. 
In addition, overexpression of miRNA-21 decreased 
GC cells sensitivity to trastuzumab by suppression of 
apoptosis; whereas suppression of miRNA-21 expres-
sion restored trastuzumab sensitivity of GC cells. 
These findings suggest that miRNA-21/PTEN path-
way may be crucial to trastuzumab acquired resistance 
mechanism in GC [66].
Breast cancer
Breast cancer remains the most frequently diagnosed 
malignancy and the primary cause of cancer-related 
death in women globally [51]. HER2 overexpression 
occurs in 10–34% of invasive breast cancers [41]. 
HER2-positive breast cancers are associated with 
more aggressive tumor phenotypes and often acquired 
resistance to therapy [67,68]. Additionally, the down-
regulation of key miRNA processing enzymes, such 
as  Drosha and Dicer, have been associated with the 
outcome, progression and recurrence of breast can-
cer. In fact, it was shown that Dicer is an indepen-
dent predictor of recurrence in the HER2-positive 
subtype [40,42,69]. Ye and coworkers showed that in 
a HER2-positive breast cancer cell line, SK-BR-3, 
miRNA-221 knockdown led to a significant decrease 
of surviving cells in the presence of trastuzumab, while 
overexpression of the pre-miRNA in question led to 
the opposite result. Trastuzumab resistance in this 
tumor model seems to be mediated by tumor suppres-
sor PTEN, since a miRNA-221  overexpression leads to 
a PTEN  downregulation [43,70].
The activation of IGF1R, an alternative growth fac-
tor receptor, represents a common feature of trastu-
zumab-refractory cells [71]. However, the underlying 
mechanism remained unclear until very recently, when 
Xing-Ming and coworkers demonstrated that epi-
genetic silencing of miRNA-375 induces trastuzumab 
resistance in HER2-positive breast cancer by targeting 
IGF1R [72]. Their findings revealed that miRNA-375 
targeted IGF1R and was downregulated in trastu-
zumab-resistant HER2-positive breast cancer cells. 
While overexpression of miRNA-375 restored trastu-
zumab sensitivity in cells, inhibition of miRNA-375 
induced trastuzumab resistance in HER2-positive 
breast cancer cells. They also showed that regulation 
of miRNA-375 expression was epigenetic since inhi-
bition of DNA methylation and histone deacetylation 
restored the expression of miRNA-375 in trastu-
zumab-resistant cells. Additionally, they found a nega-
tive correlation between the levels of miRNA-375 and 
IGF1R in breast cancer tissue samples. Lastly, epigen-
etic silencing of miRNA-375 causes IGF1R upregula-
tion, which at least partially explains the mechanism of 
trastuzumab resistance in breast cancer cells [72].
A similar work was performed by Gong et al. which 
consisted in in vitro experiments and in vivo analysis 
of HER2-positive breast cancers. HER2-positive-
trastuzumab-resistant cell lines were obtained by doing 
cell cultures in the presence of low-dose trastuzumab. 
miRNA analysis concluded that miRNA-21 was 
overexpressed in all resistant cell lines in comparison 
with parental ones. On one hand, knockdown of this 
miRNA resensitized the trastuzumab resistant breast 
cancer cells and its effects in proliferation and cell cycle. 
On the other hand, ectopic expression of miRNA-21 led 
to trastuzumab resistance in parental cell lines. Trastu-
zumab resistance mediated by miRNA-21 appears 
to be via tumor suppressor PTEN, since overexpres-
sion of this miRNA led to lower PTEN protein levels. 
Retrieving PTEN expression in resistant breast cancer 
cells restored trastuzumab activity, since this targeted 
therapy enhances PTEN phosphatase activity leading 
to AKT dephosphorylation [73]. In vivo studies were also 
performed and similar results were obtained leading to 
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Figure 1. Schematic representation of the miRNAs involved in ErbB targeted therapy acquired resistance and their targets in the 
multiple cell signaling pathways.
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the conclusion that miRNA-21 over expression in tumor 
xenografts results in resistance to trastuzumab by inhib-
iting PTEN expression. Finally, the clinical significance 
of these findings was evaluated by examining primary 
breast cancers from patients receiving trastuzumab 
therapy. miRNA-21 expression in breast cancer cells 
was reversely correlated with PTEN expression, and in 
line with a miRNA-21 upregulation, PTEN expression 
was lower in trastuzumab-resistant tumors [44].
Also, recent studies performed by Corcoran et al. 
in breast cancer cell lines revealed an involvement of 
miRNA-630 in resistance to HER-targeting drugs 
such as lapatinib, neratinib and afatinib [74]. Lapa-
tinib-resistant SKBR3 and HCC1954 cells and nera-
tinib-resistant HCC1954 cells showed a decrease in 
intra and extracellular levels of the miRNA-630 when 
compared with the parental cell lines. Transfection of 
miRNA-630 mimic to resistant cell lines enhanced the 
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Figure 2. Possible mechanisms of exosome-target cell interaction. (A) Interaction between exosomal membrane 
proteins and target cell receptors leads to intracellular signaling activation – juxtacrine fashion; (B) Interaction 
between an ectodomain, formed after protease cleavage of exosomal membrane proteins, and target cell 
receptors also leads to signaling pathways activation; (C) Fusion of the exosome with the recipient cell membrane 
and content release to the intracellular space in a nonselective manner.  
Adapted with permission from [75].
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antiproliferative effects of all the drugs in study. The 
miRNA-630 dependent resistance mechanism seems 
to be related, not only with the increase of IGF1R lev-
els, a target of miRNA-630, but also with the increase 
of EGFR and HER2 levels, targets of the drugs in 
study. The levels of the phosphorylated form of these 
proteins are also increased when miRNA-630 inhibi-
tion is performed in breast cancer cell lines. Finally, 
Corcoran et al. also proved that inhibition of the 
miRNA-630 in breast age-matched cancer cells was 
associated with increased motility, migration, invasion 
and resistance to anoikis [74].
Colorectal cancer
Colorectal cancer (CRC) is the third most common 
cancer worldwide and the fourth most common cause 
of death, affecting men and women almost equally [75]. 
The use of monoclonal antibodies against EGFR, such 
as cetuximab and panitumumab, are a common phar-
macologic approach in CRC treatment [76]. Besides the 
discovery that acquired KRAS mutations are a good 
predictive marker of cetuximab and panitumumab 
resistance in CRC, it is still unclear why certain 
patients respond to therapy and others do not [76,77].
Ragusa and coworkers made an expression pro-
file of 667 miRNAs in two human colorectal cancer 
cell lines, one cetuximab sensitive (Caco-2) and other 
cetuximab resistant (HCT-116). They identified a 
group of miRNAs differentially expressed and tested 
them in CRC patients. miRNAs let-7b and let-7e were 
downregulated in HCT-116 after cetuximab treatment, 
in which signaling downstream of KRAS remains 
activated. Let-7 family members are known to target 
KRAS, so their downregulation could be a mechanism 
that contributes to cetuximab resistance. Additionally, 
miRNA-17* (a CRC marker) is up- regulated in the resis-
tant-cell line and downregulated in the sensitive one, 
after cetuximab treatment [78]. Taken together, miRNA 
let-7b, let-7e and 17* could be considered as candidate 
 molecular markers of  cetuximab  resistance [79].
Regarding all this results, we observe that, in some 
cases, different miRNAs are involved in different 
acquired resistance mechanisms for the same drug and 
in the same tumor model. miRNAs are not specific for 
a single mRNA, moreover mRNAs and consequently 
proteins are not regulated by only one miRNA [6]. 
Additionally, signaling pathways related with ErbB 
family overlap [26]. With this being said, it is more 
likely that an acquired resistance to a targeted therapy 
would be mediated by a network of miRNAs rather 
than a single one, targeting multiple steps of different 
pathways (Figure 1). However, since miRNAs play a 
major role in targeted therapy resistance, more specifi-
cally, resistance to ErbB family targeted therapies, we 
could consider them as therapeutic options. The use of 
miRNAs mimics or inhibitors, when drug resistance is 
due to an under-expression or overexpression, respec-
tively, of the miRNA in question, should be consid-
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ered as adjuvant therapy to drugs such as cetuximab, 
 erlotinib, gefitinib and others.
The main issue regarding the use of miRNAs as 
therapeutic options is the specificity of the delivery 
in vivo. In other words, a direct delivery to the tumor, 
without affecting other body parts. Many studies have 
been made which led to huge improvements in this 
area and this introduces our next topic, exosomes.
Exosomes: a potential drug delivery model 
in EGFR-overexpressing tumors
Exosomes are membrane-bound vesicles of 40–100 nm 
in diameter present in almost all biological fluids [80]. 
They are released from most cell types, including 
cancer cells, into the extracellular space after fusion 
with the plasma membrane [81]. This type of extra-
cellular membrane vesicles are enriched in cholesterol, 
sphingo myelin and ceramide as well as lipid raft asso-
ciated proteins [81,82]. As a consequence of their origin, 
nearly all exosomes, independently of the cell type 
from which they originate, contain similar composi-
tion. However, the exosomal lumen, which is in part 
composed by mRNAs, miRNAs and other non coding 
RNAs is determined by the cell type which produced 
the exosomes [83]. In the last years, many authors 
reported differences in miRNA content when com-
paring exosomes from normal individuals with cancer 
patients [84,85]. Since exosomes are released and are able 
to circulate in most biological fluids, they can interact 
with neighboring or distant cells and ultimately lead 
to the modulation of the recipient cells [86]. There are 
three main possible mechanisms of intracellular com-
munication by exosomes. First, in a juxtacrine fashion, 
exosomal membrane proteins can interact with recep-
tors in a target cell and activate different signaling 
pathways. Second, proteases in the extracellular space 
can cleave exosomal membrane proteins, leading to a 
cleaved fragment-target cell surface receptor interac-
tion. This mechanism also activates intracellular sig-
naling. Finally, exosomes can fuse with the target cell 
membrane and release their contents, such as mRNAs 
and miRNAs, which can alter gene expression and pro-
tein translation of the recipient cell (Figure 2) [81]. The 
ability of exosomes to interact and modulate target 
cells and also their high stability in circulation makes 
them good candidates to in vivo delivery of differ-
ent molecules, such as miRNA mimics or inhibitors, 
which would allow us to surpass targeted therapies 
resistance mediated by miRNAs [87]. In fact, exosomes 
have already been used in in vivo models with differ-
ent purposes and in a wide-range of diseases [88]. More 
specifically, in cancer Phase I clinical trials, exosomes 
are being used to, either increase innate and adaptive 
immune responses against the tumor, or deliver thera-
peutic agents in a cancer-specific way [88]. Related with 
the exosomes high stability and ability of travelling in 
biological fluids, a Phase I clinical trial is investigating 
the ability of plant exosomes to deliver curcumin to 
normal and colon cancer tissue, since previous stud-
ies demonstrated that curcumin has a strong inhibi-
tory effect on the growth of colon cancer cell lines by 
 mediating signal transduction [89,90].
Regarding the focus of our review article, more 
recently, Ohno et al. showed that exosomes could 
be used as drug delivery carriers in an EGFR-over-
expressing cancer model. They used modified exo-
somes, with GE11 peptide in their membranes, to spe-
cifically deliver exosomal content to EGFR-expressing 
breast cancer cells. GE11 peptide binds to EGFR and 
is markedly less mitogenic than EGF. Also, in the same 
paper, efficient in vivo delivery of let-7a, a miRNA 
that functions as a tumor suppressor, was achieved 
by loading it to GE11+ exosomes and by injecting the 
modified exosomes intravenously in RAG2–/– mice, 
that were submitted, previously, to breast cancer cells 
transplantation [91]. This treatment suppressed tumor 
growth and no major organ damage was detected in 
the injected mice [92].
Although an exosome-based drug delivery model 
seems promising, many challenges still rise and 
have to be overcome. One of the main issues is the 
in existence of a standard technique to isolate and 
purify exosomes. Usually, ultracentrifugation is used 
to obtain exosomes, however this technique has some 
limitations since it leads to low production yield and 
contamination with protein aggregates and cellular 
debris, which may affect the quality of these nano-
vesicles [93]. Another issue is the lack of biochemically 
well-characterized exosomes and the fact that the exo-
some protein content varies depending on the cells that 
produced them [83,93]. These facts could determine the 
safety and effectiveness of an exosome-based treatment 
since certain molecules, such as MHC class I or II, 
could trigger a host immune response and eliminate 
these vesicles. Finally, the method of drug loading to 
exosomes should be optimized since the efficiency is 
relatively low [93]. Once these issues are surpassed, exo-
somes could become a novel therapeutic approach not 
only in cancer but in many other diseases allowing a 
more specific and potent drug effect.
Conclusion
miRNAs are an important epigenetic mechanism of 
acquired resistance to targeted therapies by cancer 
cells. Despite great findings lately, this subject still 
needs further research in order to completely under-
stand the mechanisms underlying acquired resistance 
of different drugs in a wider range of tumor types. 
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Executive summary
miRNAs
•	 miRNAs are a class of noncoding RNAs that control gene expression by either degrading or blocking 
translation of mRNAs.
•	 A miRNA is not specific for a certain mRNA, it can regulate up to 100 different mRNAs and is also described 
that more than 10,000 mRNAs seem to be regulated by miRNAs.
•	 Changes in miRNA levels may have an effect in treatment response, since targeted therapies are used for 
specific proteins and signal pathways related with biological processes, which are regulated by miRNAs.
Cancer treatment
•	 Chemotherapy and radiotherapy target, but not exclusively, cancer cells, causing several side-effects. Target 
therapy emerged in order to minimize those side-effects.
•	 Despite all the latest developments and improvements in cancer therapy, resistance to treatment still exists.
•	 Acquired chemotherapy drug resistance can be modulated by genetic and/or epigenetic factors. In fact, 
recent data demonstrate that certain miRNAs activity might be altered in order to achieve chemotherapy 
resistance.
•	 The ErbB/HER receptors family regulate apoptosis, cell cycle progression, cytoskeletal rearrangement and 
many other biological processes. Mutations or increased expression of ErbB family members occur in several 
malignancies, thus different ErbB/HER targeted therapies have been developed against this family of receptors.
•	 miRNAs may be a way not only to unveil resistance mechanisms but also, if used as a treatment option, to 
overcome targeted therapy limitations.
miRNAs & targeted therapy resistance
•	 One potential mechanism of acquired resistance to cetuximab in head and neck squamous cell carcinoma 
involves the increased expression of HB-EGF due to a decrease in miRNA-212 expression. HB-EGF promotes 
cetuximab resistance since it activates receptor kinases other than EGFR, like HER3 and MET.
•	 High expression levels of miRNA-21 are associated with gefitinib resistance in non-small-cell lung cancer 
(NSCLC) cell lines and also with trastuzumab resistance in HER2 positive gastric and breast cancer cell lines. 
The upregulation of this miRNA leads to a PTEN downregulation, which is involved in PI3K-AKT pathway. 
PTEN protein dephosphorylates PI3K that mediates activation of AKT, ultimately leading to AKT pathway 
inactivation.
•	 miRNA-214 and miRNA-221 overexpression are associated with gefitinib resistance in a lung adenocarcinoma 
cell line and trastuzumab resistance in a breast cancer cell line, respectively. Since PTEN is a target of these 
miRNAs, the resistance mechanism is also based in a PI3K/AKT pathway activation.
•	 In different lung cancer cell lines it has been demonstrated that TGF-β–miRNA200–MIG6 pathway coordinates 
the EMT-associated kinase switch that induces resistance to erlotinib.
•	 Garofalo and coworkers demonstrated that changes in MET and EGFR-related miRNAs levels, more specifically, 
miRNA-30c, miRNA-103, miRNA-203, miRNA-221 and miRNA-222 levels, had a significant role in gefitinib 
resistance on NSCLC cell lines and in vivo models.
•	 The overexpression of miRNA-374a and the downregulation of miRNA-548b have been correlated with Axl 
kinase overexpression that is involved in acquired resistance to gefitinib in NSCLC.
•	 miRNA-375 downregulation by epigenetic silencing causes IGF1R upregulation, which leads to trastuzumab 
resistance in HER2-positive breast cancer.
•	 In breast cancer cell lines, miRNA-630 downregulation is associated with resistance to HER-targeting drugs 
such as lapatinib, neratinib and afatinib. The miRNA-630 dependent resistance mechanism seems to be 
related, not only with the increase of IGF1R levels, a target of miRNA-630, but also with the increase of EGFR 
and HER2 levels, targets of the drugs in study.
•	 Let-7 family members are known to target KRAS, so let-7b and let7-e downregulation could be a mechanism 
that contributes to cetuximab resistance in colorectal cancer.
Exosomes: a potential drug delivery model in EGFR-overexpressing tumors
•	 Exosomes are membrane-bound vesicles released from most cell types, including cancer cells.
•	 The exosomal lumen, which is in part composed by mRNAs, miRNAs and other noncoding RNAs is determined 
by the cell type which produced the exosomes.
•	 Exosomes can interact with surroundings or distant cells and ultimately lead to the modulation of the 
recipient cells, since they are able to circulate in most biological fluids.
•	 The ability of exosomes to interact and modulate target cells and also their high stability in circulation makes 
them good candidates to in vivo delivery of different molecules, such as miRNA mimics or inhibitors.
•	 In Phase I clinical trials, exosomes are being used to, either increase innate and adaptive immune responses 
against the tumor, or deliver therapeutic agents in a cancer-specific way.
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Ultimately, these findings would allow a better under-
standing of tumor biology and therapy response, 
enforcing the development of a treatment even more 
personalized and efficient. In this review, we have 
highlighted miRNAs and their role in the develop-
ment of acquired resistance to ErbB family targeted 
 therapies in  different cancer models.
Future perspective
In the future, miRNAs could be used as biomarkers 
for treatment response, through an expression profile, 
and also as therapeutic options. Modified exosomes 
carrying antitumor miRNAs are a promising drug 
 delivery model that can revolutionize today’s approach 
of  cancer treatment.
Financial & competing interests disclosure
The authors would like to thank the Liga Portuguesa Contra o 
Cancro – Núcleo Regional do Norte- LPCC-NRN (Portuguese 
League Against Cancer) and Fundação para a Ciência e Tecno-
logia- FCT (Portuguese Foundation for Science and Technol-
ogy). F Dias is recipient of research scholarship awarded by 
LPCC-NRN. AL Teixeira is a research fellow from the strate-
gic funding of the FCT (PCT: PEst- UID/DTP/00776/2013 and 
COMPETE: POCI-01-0145-FEDER-006868). The authors have 
no other relevant affiliations or financial involvement with any 
organization or entity with a financial interest in or financial 
conflict with the subject matter or materials  discussed in the 
manuscript apart from those disclosed.
No writing assistance was utilized in the production of this 
manuscript.
References
Papers of special note have been highlighted as:  
• of interest; •• of considerable interest
1 Zhang J, Zhao H, Gao Y, Zhang W. Secretory miRNAs as 
novel cancer biomarkers. Biochim. Biophys. Acta 1826(1), 
32–43 (2012).
2 Shi X-B, Tepper CG, Devere White RW. Cancerous 
miRNAs and their regulation. Cell Cycle (TX, USA) 7(11), 
1529–1538 (2008).
3 Jansson MD, Lund AH. MicroRNA and cancer. Mol. Oncol. 
6(6), 590–610 (2012).
4 Horikawa Y, Wood CG, Yang H et al. Single nucleotide 
polymorphisms of microRNA-machinery genes modify 
the risk of renal cell carcinoma. Clin. Cancer Res. 14(23), 
7956–7962 (2008).
5 Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CMP. 
Delivering the promise of miRNA cancer therapeutics. Drug 
Discov. Today 18(5–6), 282–289 (2013).
6 Hummel R, Hussey DJ, Haier J. MicroRNAs: predictors and 
modifiers of chemo- and radiotherapy in different tumour 
types. Eur. J. Cancer 46(2), 298–311
7 Slezak-Prochazka I, Durmus S, Kroesen B-J, Van Den 
Berg A. MicroRNAs, macrocontrol: regulation of miRNA 
processing. RNA 16(6), 1087–1095 (2010).
8 Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions 
and down-regulation of micro-RNA genes miR15 and miR16 
at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. 
Sci. USA 99(24), 15524–15529 (2002).
9 Croce CM. Causes and consequences of microRNA 
dysregulation in cancer. Nat. Rev. Genet. 10(10), 704–714 
(2009).
10 Cho WCS. MicroRNAs: Potential biomarkers for cancer 
diagnosis, prognosis and targets for therapy. Int. J. Biochem. 
Cell Biol. 42(8), 1273–1281 (2010).
11 Dias F, Teixeira AL, Santos JI et al. Renal cell carcinoma 
development and miRNAs: a possible link to the EGFR 
pathway. Pharmacogenomics 14(14), 1793–1803 (2013).
12 He L, Thomson JM, Hemann MT et al. A microRNA 
polycistron as a potential human oncogene. 
Nature 435(7043), 828–833 (2005).
13 Hossain A, Kuo MT, Saunders GF. Mir-17-5p regulates 
breast cancer cell proliferation by inhibiting translation of 
AIB1 mRNA. Mol. Cell. Biol. 26(21), 8191–8201 (2006).
14 Luqmani YA. Mechanisms of drug resistance in cancer 
chemotherapy. Med. Princ. Pract. 14(Suppl. 1), 35–48 (2005).
15 Gerber DE. Targeted therapies: a new generation of cancer 
treatments. Am. Fam. Physician 77(3), 311–319 (2008).
16 Hoelder S, Clarke PA, Workman P. Discovery of small 
molecule cancer drugs: successes, challenges and opportunities. 
Mol. Oncol. 6(2), 155–176 (2012).
17 Huang ME, Ye YC, Chen SR et al. Use of all-trans retinoic 
acid in the treatment of acute promyelocytic leukemia. Blood 
72(2), 567–572 (1988).
18 O’Brien SG, Guilhot F, Larson RA et al. Imatinib compared 
with interferon and low-dose cytarabine for newly diagnosed 
chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 
348(11), 994–1004 (2003).
19 Druker BJ, Guilhot F, O’Brien SG et al. Five-year follow-up 
of patients receiving imatinib for chronic myeloid leukemia. 
N. Engl. J. Med. 355(23), 2408–2417 (2006).
20 Li H, Yang BB. Friend or foe: the role of microRNA in 
chemotherapy resistance. Acta Pharmacol. Sin. 34(7), 
870–879 (2013).
21 Dean M, Rzhetsky A, Allikmets R. The human ATP-binding 
cassette (ABC) transporter superfamily. Genome Res. 11(7), 
1156–1166 (2001).
22 Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine 
kinase inhibitors. Acta Pharm. Sin. B 5(5), 390–401 (2015).
23 Shi Z, Tiwari AK, Shukla S et al. Sildenafil reverses ABCB1- 
and ABCG2-mediated chemotherapeutic drug resistance. 
Cancer Res. 71(8), 3029–3041 (2011).
24 Garofalo M, Croce CM. MicroRNAs as therapeutic targets 
in chemoresistance. Drug Resist. Updat. 16(3), 47–59 (2013).
••	 Extensive	review	regarding	the	involvement	of	microRNAs	
in	chemotherapy	resistance	and	the	possibility	of	
microRNA-based	cancer	treatment.
25 Schechter AL, Stern DF, Vaidyanathan L et al. The neu 
oncogene: an erb-B-related gene encoding a 185,000-Mr 
tumour antigen. Nature 312(5994), 513–516 (1984).
10.2217/pgs-2016-0038www.futuremedicine.comfuture science group
miRNAs: mediators of ErbB family targeted therapy resistance    Review
26 Yarden Y, Sliwkowski MX. Untangling the ErbB signalling 
network. Nat. Rev. Mol. Cell Biol. 2(2), 127–137 (2001).
•	 Reviews	the	complex	network	of	signaling	pathways	activated	
by	the	ErbB	receptors	family	and	their	impact	in	cancer.
27 Yarden Y, Pines G. The ERBB network: at last, cancer 
therapy meets systems biology. Nat. Rev. Cancer 12(8), 
553–563 (2012).
28 Roskoski Jr R. The ErbB/HER family of protein-tyrosine 
kinases and cancer. Pharmacol. Res. 79(0), 34–74 (2014).
29 Teixeira AL, Gomes M, Medeiros R. EGFR signaling pathway 
and related-miRNAs in age-related diseases: the example of 
miR-221 and miR-222. Front. Genet. 3, 286 (2012).
30 Normanno N, Bianco C, De Luca A, Maiello MR, Salomon 
DS. Target-based agents against ErbB receptors and their 
ligands: a novel approach to cancer treatment. Endocr. Relat. 
Cancer 10(1), 1–21 (2003).
31 Vogelstein B, Papadopoulos N, Velculescu VE, Zhou 
S, Diaz LA, Kinzler KW. Cancer genome landscapes. 
Science 339(6127), 1546–1558 (2013).
32 Garraway LA, Jänne PA. Circumventing cancer drug 
resistance in the era of personalized medicine. Cancer Discov. 
2(3), 214–226 (2012).
33 Hatakeyama H, Cheng H, Wirth P et al. Regulation of 
heparin-binding EGF-like growth factor by miR-212 and 
acquired cetuximab-resistance in head and neck squamous 
cell carcinoma. PLoS ONE 5(9), e12702 (2010).
•	 One	of	the	first	studies	demonstrating	the	involvement	
of	a	microRNA	in	acquired	resistance	to	an	ErbB	family	
targeted	therapy.
34 Izumchenko E, Chang X, Michailidi C et al. The TGFβ–
miR200–MIG6 pathway orchestrates the EMT-associated 
kinase switch that induces resistance to EGFR inhibitors. 
Cancer Res. 74(14), 3995–4005 (2014).
35 El-Awady RA, Herzi F, Al-Tunaiji H et al. Epigenetics and 
miRNA as predictive markers and targets for lung cancer 
chemotherapy. Cancer Biol. Ther. 16(7), 1056–1070 (2015).
36 Nakamura K, Yano H, Schaefer E, Sabe H. Different modes 
and qualities of tyrosine phosphorylation of Fak and Pyk2 
during epithelial-mesenchymal transdifferentiation and cell 
migration: analysis of specific phosphorylation events using 
site-directed antibodies. Oncogene 20(21), 2626–2635 (2001).
37 Engelman JA, Zejnullahu K Fau, Mitsudomi T, Mitsudomi 
T Fau Song Y et al. MET amplification leads to gefitinib 
resistance in lung cancer by activating ERBB3 signaling. 
Science 316(5827), 1039–1043 (2007).
38 Mellinghoff IK, Cloughesy TF, Mischel PS. PTEN-mediated 
resistance to epidermal growth factor receptor kinase 
inhibitors. Clin. Cancer Res. 13(2), 378–381 (2007).
39 Kamangar F, Dores GM, Anderson WF. Patterns of cancer 
incidence, mortality, and prevalence across five continents: 
defining priorities to reduce cancer disparities in different 
geographic regions of the world. J. Clin. Oncol. 24(14), 
2137–2150 (2006).
40 Murria Estal R, Palanca Suela S, Juan Jiménez I et al. 
MicroRNA signatures in hereditary breast cancer. Breast 
Cancer Res. Treat. 142(1), 19–30 (2013).
41 Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. 
Diagn. Mol. Pathol. 10(3), 139–152 (2001).
42 Khoshnaw SM, Rakha EA, Abdel-Fatah T et al. The 
microRNA maturation regulator Drosha is an independent 
predictor of outcome in breast cancer patients. Breast Cancer 
Res. Treat. 137(1), 139–153 (2012).
43 Ye X, Bai W, Zhu H et al. MiR-221 promotes trastuzumab-
resistance and metastasis in HER2-positive breast cancers by 
targeting PTEN. BMB Rep. 47(5), 268–273 (2014).
44 Gong C, Yao Y, Wang Y et al. Up-regulation of miR-21 
mediates resistance to trastuzumab therapy for breast cancer. 
J. Biol. Chem. 286(21), 19127–19137 (2011).
45 Johansson A-C, Ansell A, Jerhammar F et al. Cancer-
associated fibroblasts induce matrix metalloproteinase–
mediated cetuximab resistance in head and neck squamous cell 
carcinoma cells. Mol. Cancer Res. 10(9), 1158–1168 (2012).
46 Price KR, Cohen E. Current treatment options for metastatic 
head and neck cancer. Curr. Treat. Options Oncol. 13(1), 
35–46 (2012).
47 Wen Y, Grandis JR. Emerging drugs for head and neck 
cancer. Expert Opin. Emerg. Drugs 20(2), 313–329 (2015).
48 Smith JP, Pozzi A, Dhawan P, Singh AB, Harris RC. Soluble 
HB-EGF induces epithelial-to-mesenchymal transition in 
inner medullary collecting duct cells by upregulating Snail-2. 
Am. J. Physiol. Renal Physiol. 296(5), F957–F965 (2009).
49 Yagi H, Yotsumoto F, Miyamoto S. Heparin-binding 
epidermal growth factor-like growth factor promotes 
transcoelomic metastasis in ovarian cancer through 
epithelial–mesenchymal transition. Mol. Cancer Ther. 7(10), 
3441–3451 (2008).
50 Wang F, Liu R, Lee SW, Sloss CM, Couget J, Cusack 
JC. Heparin-binding EGF-like growth factor is an 
early response gene to chemotherapy and contributes to 
chemotherapy resistance. Oncogene 26(14), 2006–2016 
(2006).
51 Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 
Global cancer statistics. CA Cancer J. Clin. 61(2), 69–90 
(2011).
52 Wozniak MB, Scelo G, Muller DC, Mukeria A, Zaridze 
D, Brennan P. Circulating MicroRNAs as non-invasive 
biomarkers for early detection of non-small-cell lung cancer. 
PLoS ONE 10(5), e0125026 (2015).
53 Yu HA, Arcila ME, Rekhtman N et al. Analysis of tumor 
specimens at the time of acquired resistance to EGFR-TKI 
therapy in 155 patients with EGFR-mutant lung cancers. 
Clin. Cancer Res. 19(8), 2240–2247 (2013).
54 Gao W, Lu X, Liu L, Xu J, Feng D, Shu Y. MiRNA-21. 
Cancer Biol. Ther. 13(5), 330–340 (2012).
55 Bao L, Yan Y, Xu C et al. MicroRNA-21 suppresses PTEN 
and hSulf-1 expression and promotes hepatocellular 
carcinoma progression through AKT/ERK pathways. 
Cancer Lett. 337(2), 226–236 (2013).
56 Shen H, Zhu F, Liu J et al. Alteration in Mir-21/PTEN 
expression modulates gefitinib resistance in non-small cell 
lung cancer. PLoS ONE 9(7), e103305 (2014).
57 Yip PY. Phosphatidylinositol 3-kinase-AKT-mammalian 
target of rapamycin (PI3K–AKT–mTOR) signaling pathway 
10.2217/pgs-2016-0038 Pharmacogenomics (Epub ahead of print) future science group
Review    Adem, Bastos, Dias, Teixeira & Medeiros
in non-small cell lung cancer. Transl. Lung Cancer Res. 4(2), 
165–176 (2015).
58 Benedettini E, Sholl LM, Peyton M et al. Met activation 
in non-small cell lung cancer is associated with de novo 
resistance to EGFR inhibitors and the development of brain 
metastasis. Am. J. Pathol. 177(1), 415–423 (2010).
59 Garofalo M, Romano G, Di Leva G et al. EGFR and MET 
receptor tyrosine kinase-altered microRNA expression 
induces tumorigenesis and gefitinib resistance in lung 
cancers. Nat. Med. 18(1), 74–82 (2011).
60 Wang YS, Wang YH, Xia HP, Zhou SW, Schmid-Bindert G, 
Zhou CC. MicroRNA-214 regulates the acquired resistance 
to gefitinib via the PTEN/AKT pathway in EGFR-mutant 
cell lines. Asian Pac. J. Cancer Prev. 13(1), 255–260 (2012).
61 Yamasaki F, Johansen MJ, Zhang D et al. Acquired resistance 
to erlotinib in A-431 epidermoid cancer cells requires 
down-regulation of MMAC1/PTEN and up-regulation of 
phosphorylated Akt. Cancer Res. 67(12), 5779–5788 (2007).
62 Zhang Z, Lee JC, Lin L et al. Activation of the AXL kinase 
causes resistance to EGFR-targeted therapy in lung cancer. 
Nat. Genet. 44(8), 852–860 (2012).
63 Wang Y, Xia H, Zhuang Z, Miao L, Chen X, Cai H. Axl-
altered microRNAs regulate tumorigenicity and gefitinib 
resistance in lung cancer. Cell Death Dis. 5(5), e1227 (2014).
64 Bang Y-J, Van Cutsem E, Feyereislova A et al. Trastuzumab 
in combination with chemotherapy versus chemotherapy 
alone for treatment of HER2-positive advanced gastric or 
gastro-oesophageal junction cancer (ToGA): a Phase 3, 
open-label, randomised controlled trial. Lancet 376(9742), 
687–697 (2010).
65 Lee JY, Hong M, Kim ST et al. The impact of concomitant 
genomic alterations on treatment outcome for trastuzumab 
therapy in HER2-positive gastric cancer. Sci. Rep. 5, 9289 
(2015).
66 Eto K, Iwatsuki M, Watanabe M et al. The microRNA-21/
PTEN pathway regulates the sensitivity of HER2-positive 
gastric cancer cells to trastuzumab. Ann. Surg. Oncol. 21(1), 
343–350 (2014).
67 Ross JS, Fletcher JA. The HER-2/neu oncogene in breast 
cancer: prognostic factor, predictive factor, and target for 
therapy. Stem Cells 16(6), 413–428 (1998).
68 Ross JS, Fletcher JA, Bloom KJ et al. Targeted therapy in 
breast cancer: The HER-2/neu gene and protein. Mol. Cell. 
Proteomics 3(4), 379–398 (2004).
69 Khoshnaw SM, Rakha EA, Abdel-Fatah TM et al. Loss of 
Dicer expression is associated with breast cancer progression 
and recurrence. Breast Cancer Res. Treat. 135(2), 403–413 
(2012).
70 Teixeira A, Ferreira M, Silva J et al. Higher circulating 
expression levels of miR-221 associated with poor overall 
survival in renal cell carcinoma patients. Tumor Biol. 35(5), 
4057–4066 (2014).
71 Nahta R, Yuan LXH, Zhang B, Kobayashi R, Esteva FJ. 
Insulin-like growth factor-I receptor/human epidermal 
growth factor receptor 2 heterodimerization contributes 
to trastuzumab resistance of breast cancer cells. Cancer 
Res. 65(23), 11118–11128 (2005).
72 Ye X-M, Zhu H-Y, Bai W-D et al. Epigenetic silencing of 
miR-375 induces trastuzumab resistance in HER2-positive 
breast cancer by targeting IGF1R. BMC Cancer 14, 134–134 
(2014).
73 Nagata Y, Lan K-H, Zhou X et al. PTEN activation 
contributes to tumor inhibition by trastuzumab, and loss of 
PTEN predicts trastuzumab resistance in patients. Cancer 
Cell 6(2), 117–127 (2004).
74 Corcoran C, Rani S, Breslin S et al. miR-630 targets IGF1R 
to regulate response to HER-targeting drugs and overall 
cancer cell progression in HER2 over-expressing breast 
cancer. Mol. Cancer 13, 71–71 (2014).
75 Haggar FA, Boushey RP. Colorectal cancer epidemiology: 
incidence, mortality, survival, and risk factors. Clin. Colon 
Rectal Surg. 22(4), 191–197 (2009).
76 Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour 
J, Bardelli A. Biomarkers predicting clinical outcome 
of epidermal growth factor receptor-targeted therapy in 
metastatic colorectal cancer. J. Natl Cancer Inst. 101(19), 
1308–1324 (2009).
77 Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras 
mutations and benefit from cetuximab in advanced 
colorectal cancer. N. Engl. J. Med. 359(17), 1757–1765 
(2008).
78 Ng EKO, Chong WWS, Jin H et al. Differential expression 
of microRNAs in plasma of patients with colorectal cancer: a 
potential marker for colorectal cancer screening. Gut 58(10), 
1375–1381 (2009).
79 Ragusa M, Majorana A, Statello L et al. Specific alterations 
of microRNA Transcriptome and global network structure in 
colorectal carcinoma after cetuximab treatment. Mol. Cancer 
Ther. 9(12), 3396–3409 (2010).
80 Simons M, Raposo G. Exosomes – vesicular carriers for 
intercellular communication. Curr. Opin. Cell Biol. 21(4), 
575–581 (2009).
81 Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular 
organelles important in intercellular communication. 
J. Proteomics 73(10), 1907–1920 (2010).
82 Simpson RJ, Jensen SS, Lim JWE. Proteomic profiling of 
exosomes: current perspectives. Proteomics 8(19), 4083–4099 
(2008).
83 Sato-Kuwabara Y, Melo SA, Soares FA, Calin GA. The 
fusion of two worlds: non-coding RNAs and extracellular 
vesicles – diagnostic and therapeutic implications (Review). 
Int. J. Oncol. 46(1), 17–27 (2015).
84 Skog J, Wurdinger T, Van Rijn S et al. Glioblastoma 
microvesicles transport RNA and protein that promote 
tumor growth and provide diagnostic biomarkers. Nat. Cell 
Biol. 10(12), 1470–1476 (2008).
85 Rabinowits G, Gerçel-Taylor C, Day JM, Taylor DD, 
Kloecker GH. Exosomal microRNA: a diagnostic marker for 
lung cancer. Clin. Lung Cancer 10(1), 42–46
86 Salido-Guadarrama I, Romero-Cordoba S, Peralta-
Zaragoza O, Hidalgo-Miranda A, Rodríguez-Dorantes 
M. MicroRNAs transported by exosomes in body fluids as 
mediators of intercellular communication in cancer. Onco 
Targets Ther. 7, 1327–1338 (2014).
10.2217/pgs-2016-0038www.futuremedicine.comfuture science group
miRNAs: mediators of ErbB family targeted therapy resistance    Review
•	 Recent	publication	giving	a	good	overview	of	the	
importance	of	microRNAs	and	exosomes	in	cancer	cell	
communication	and	overall	cancer	development.
87 Kalra H, Adda CG, Liem M et al. Comparative proteomics 
evaluation of plasma exosome isolation techniques and 
assessment of the stability of exosomes in normal human 
blood plasma. Proteomics 13(22), 3354–3364 (2013).
88 Suntres ZE, Smith MG, Momen-Heravi Fet al. Therapeutic 
uses of exosomes. Exosomes Microvesicles 1(5), 33–40 (2013).
89 Johnson SM, Gulhati PaT, Arrieta I et al. Curcumin inhibits 
proliferation of colorectal carcinoma by modulating Akt/
mTOR signaling. Anticancer Res. 29(8), 3185–3190 (2009).
90 James Graham Brown Cancer Center; University of 
Louisville. Study investigating the ability of plant exosomes 
to deliver curcumin to normal and colon cancer tissue. NLM 
identifier: NCT01294072  
https://clinicaltrials.gov/show/NCT01294072  
••	 First	clinical	trial	that	explores	the	possibility	of	using	
exosomes	as	a	drug	delivery	model	in	cancer	treatment.
91 Liu K, Zhang C, Li T et al. Let-7a inhibits growth and 
migration of breast cancer cells by targeting HMGA1. Int. J. 
Oncol. 46(6), 2526–2534 (2015).
92 Ohno S-I, Takanashi M, Sudo K et al. Systemically injected 
exosomes targeted to EGFR deliver antitumor microRNA to 
breast cancer cells. Mol. Ther. 21(1), 185–191 (2013).
••	 First	study	using	modified	exosomes	containing	a	tumor	
suppressor	microRNA, in vivo	as	a	new	therapeutic	
approach	in	EGFR-overexpressing	tumors.
93 Ren J, He W, Zheng L, Duan H. From structures to 
functions: insights into exosomes as promising drug delivery 
vehicles. Biomater. Sci. doi:10.1039/C5BM00583C (2016) 
(Epub ahead of print).
